Subject Index to Volume 76

A

Acetyl-CoA carboxylase gene, insulin regulation of expression, 1116
α-Acid glycoprotein gene, insulin regulation of expression, 1120–1121
Acoustic sensitization, *Drosophila*, 314
Actin(s)
  breast, myoepithelial cell expression, 74–75
  in sarcomeric muscles, 373
Actin cytoskeleton
  cell-cell contacts, 264–266
  epithelial cell polarity, 262
  membrane-associated cytoskeleton, 263–264
  protein trafficking, 266–267
α-Actinin, in sarcomeric muscle, 382
β-Actinin. *See* CapZ protein
Action potentials, taste cells, 726–728
Adenine nucleotides, ryanodine receptor activity, 556
Adenosine
  cardiovascular control interactions, 214
  formation and release, 472
  interstitial fluid concentrations, 472–473
  P_1 receptors, 469–470
  renal responses to hypoxia/ischemia, 479
  renal vascular actions, 473–476
    actions of adenosine analogues mediated by A_1 and A_2 receptors, 473–474
    adenosine-angiotensin II interactions, 476–477
    effects of altering interstitial/perivascular adenosine, 474–475
    interactions with other paracrine systems, 476–478
    interactions with other vasoactive factors, 477–478
    microvascular responses to adenosine agonists, 475–476
    regulation of renin secretion, 478–479
    renal hemodynamic actions, 473
    responses to blockade of endogenous adenosine, 476
  renin secretion and, 478–479
Adenosine analogues, renal vascular actions, 473–474
  microvascular responses, 475–476
Adenosine 3′,5′-cyclic monophosphate (cAMP)
  bitter taste transduction, 738–739
  renal vascular control, 430
  signaling, *Drosophila* learning mutants affecting, 305–307
  sweet taste transduction, 731
Adenosinetriphosphatase (ATPase)
  calcium, sarcoplasmic reticulum, 971
  myosin
    activity, 395–398
    ATPase kinetics and myosin isoforms, 398–400
  proton, proximal renal tubule, 279
  sodium-potassium, protein trafficking in renal epithelium, 280–281
Adenosine 5′-triphosphate (ATP)
  cardiac potassium channel regulation, 60–61
  formation and release, 470–471
  hydrolysis, chemomechanical transduction in sarcomeric muscle, 395–400
  metabolism, 471–472
  P_2 receptors, 470
  renal vascular actions, 479–483
    cellular mechanisms of action, 482–483
    direct vs. indirect effects, 481–482
    dual actions, 479–480
    single-nephron and microvascular responses, 480–481
Adipocyte(s), breast, 89
Adrenal gland, parathyroid hormone-related protein in, 160–161
Aging, cardiovascular control interactions in, 220–221
Aldosterone, salty taste reception, 747–748
Alkylphosphonates, in energy metabolism, nuclear magnetic resonance spectroscopy, 827–828
Amidation, gastrin processing, 779–780
Amiloride, salty taste reception, 745
Amines
  gastric endocrine cells, 786–788
  G cells, 787–788
Amine transporters, 775
Amino acids, taste receptors (sensing), 734–735
γ-Aminobutyric acid, G cells, 787–788
Amnion, parathyroid hormone-related protein in, 153
Amphibians, regeneration of spinal pathways in lesioned spinal cords, 332–333
Amphiphilic peptides, in bitter taste, 737–738
α-Amylase gene, insulin regulation of expression, 1117
Anesthetics
  metabolic consequences, 813–814
  volatile, actions in MHS muscle, 573–579. *See also* Halothane
Angiotensin-converting enzyme (ACE) inhibitors, renal vascular response to, 461–462
  kinin-mediated component, 462–463
Angiotensin I, intracellular formation, 457
Angiotensin II. *See also* Endothelial factors
  actions on renal microvasculature, 459–465. *See also* Renal microcirculation, angiotensin II actions
    adenosine-angiotensin II interactions, 476–477
  arachidonic acid metabolite interactions, 492–493
  blockade, segmental renal microcirculatory responses to, 463–464
  cardiovascular control interactions, 212–214
  differential activation and signal transduction mechanisms, 467–469
    activation of membrane channels, 467–468
    in afferent and efferent arterioles, 468–469
    intracellular signaling mechanisms mediating, 467
  extrarenal and intrarenal formation, 456–458
  interactions between renal vascular and tubular effects, 465–467
  interactions with sympathetic nervous system in regulation of renal hemodynamics, 465
  intracellular formation, 457–458
  intrarenally formed, 457
    role of, 464–465

renal vascular actions, medullary circulation, 500–501
tubuloglomerular feedback responsiveness and, 465–467
Angiotensin II receptors
blockade
indirect effects on renal hemodynamics, 464
renal vascular response, 461–462
in renal vasculature, 458–459
Annexins, in synaptic vesicle docking and fusion, 16
Anoxia, environmental, energy metabolism in invertebrates and, 804–806
Antidiuretic hormone, salty taste reception, 748
Aorta, vascular smooth muscle, culture studies, 84–85
AP-1 motif, insulin regulation of gene expression, 1120, 1132–1134
AP-1 transcription factors, molecular adaptation to hypoxia, 864–865
Apolipoprotein(s)
apo CIII, in hypertriglyceridemia, 1145
insulin-regulated gene expression, 1143–1144
Aquaporins, in renal collecting duct principal cells, 281–283
Arachidonic acid metabolites
angiotensin II interactions, 492–493
cyclooxygenase metabolites, 487–490
cytochrome *P*-450 metabolites, 491–492
formation and relative prominence in kidney, 485–487
interactions with other vasoconstrictors, 493–494
interactions with other vasodilators, 494–495
lipoxygenase metabolites, 490–491
modulation of renal vascular actions of other paracrine systems, 492–495
renal blood flow autoregulation, 495
renal vascular actions, 485–497
tubuloglomerular feedback mechanism and, 496–497
Arena platform reward learning, *Drosophila*, 314
Arginine vasopressin, renal vascular actions, 498–500
Arrhythmias, lethal, cardiac potassium channel gene defects and, 61–62
Arterial baroreceptors
cardiovascular control, 200–202
interaction with nitric oxide, short-term blood pressure control, 206–207
Atherosclerosis, colony stimulating factor-1 and macrophage scavenger receptor expression in, 941–942
Autoregulation
cardiovascular control, 199
central control interactions, in cardiovascular control, 214–215
renal microcirculation. *See also* Renal microcirculation, autoregulation
nitric oxide in, 438–439
Axon(s), regeneration, in spinal cord injury. *See* Spinal cord injury

B

Bacteria
enteric, oxidative stress, 845–846
Escherichia coli. *See Escherichia coli*
heme biosynthetic pathway, 849–850
hemoglobins, 848–849
proposed role as "oxygen sensor," 849
structure-function, 848–849
outer membrane, 1074–1075. *See also* Porins
oxygen sensing, 841–850. *See also* Oxygen, effects on bacteria
symbiotic diazotrophs, nitrogen fixation, 846–848
Baroreceptor resetting, 204
Baroreflex, cardiovascular control, 200–202
Basal stem cells, taste buds, 724
Behavior, pattern generator control, 688
Biliary tree. *See* Hepatobiliary system
Bitter taste. *See* Taste reception
Blood flow
changes, in spinal cord injury, 322
renal. *See* Renal microcirculation
Blood gases, cardiovascular control interactions and, 218–220
Blood pressure. *See also* Cardiovascular control interactions
control, renal medullary circulation and, 505
regulation, vasopressin in, 210–211
short-term control, arterial baroreceptors-nitric oxid interaction, 206–207
Bone, development, differentiation, and cell death, insulin-like growth factor action, 1017
Bradykinin
receptor blockade, renal vascular responses to, 455–456
in renal vascular control, 454–456
medullary circulation, 502–503
vasodilator action, mechanisms of, 455
Brain. *See also* Central nervous system
Drosophila learning mutants, 300–302
parathyroid hormone-related protein in, 151–152
sodium channels. *See* Sodium channel(s), cardiac and nerve channels
Breast
adipocytes, 89
cytokeratins
luminal epithelial cell expression, 73
myoepithelial cell expression, 73–74
development, 69
endothelial cells, 86
in culture, 86
markers, 86
estrogen receptors, 72–73
fibroblasts, 81–82
in culture, 81–82
phenotype preservation, 82
isolation, 82
markers, 81
histology, normal, 69–71
luminal epithelial cells, 71–73
culture, 77–81
in culture, 79–80
cytokeratins, 73

episialin/sialomucin, 72
estrogen receptors, 72–73
markers, 71–73
macrophages, 89
malignant transformation. *See* Breast cancer
microvasculature, 70–71
vascular smooth muscle cells, 82–86
myoepithelial cells
actins, 74–75
caldesmon and calponin, 76–77
in culture, 78–79
restoration of myoepithelial differentiation, 79
cytokeratins, 73–74
markers, 73–77
myosins, 75–76
normal cells, 69–89
adipocytes, 89
endothelial cells, 86
fibroblasts, 81–82
histology, 69–71
luminal epithelial cells, 71–73
macrophages, 89
myoepithelial cells, 73–77
pericytes, 86–89
primary culture, 77–81. *See also* Breast, primary culture
vascular smooth muscle cells, 82–86
parathyroid hormone-related protein in, 138–140
parenchymal cells, 70
pericytes, 86–89
in culture, 89
isolation of, 89
markers, 86–89
primary culture, 77–81
culture media for normal epithelial cells, 80–81
endothelial cells in, 86
fibroblasts, 81–82
luminal epithelial cell modification, 79–80
monolayer culture, 77
monolayer culture "artifact," 78–79
myoepithelial cell modification, 77–78
restoration of myoepithelial differentiation, 79
stroma, 70
vascular smooth muscle cells, 82–86
culture, 85–86
isolation of, 83–84
markers, 82
Breast cancer, 89–107
cellular conversion, 92–96
models of cellular conversion and origin of cancer in culture, 94–96
cellular origin, 92–94
models of cellular conversion and origin of cancer in culture, 94–96
histology, 89–92
matrix degradation, 105–107
models of human breast cancer cells in culture, 96–99
established malignant cell lines, 96
identification of cancer cells in primary culture assays, 96–98
obtaining proliferating cells, 98–99
primary monolayer culture assays, 96
models of stromal cell conversion in culture, 101–103
paracrine scenario, 103–105
factors from stromal cells, 105
myogenic factors, 103–104
nonmyogenic factors, 104–105
perspective and conclusion, 107–108
stromal reaction, 99–101
extracellular matrix, 99–100
initiation, 99
models of stromal cell conversion in culture, 101–103
paracrine scenario, 103–105
stromal cells, 100–101
transforming growth factor-β in, 103–104
Brody's disease, 567

C

Caffeine
in malignant hyperthermia-susceptible human muscle, 572–573
in malignant hyperthermia-susceptible pig muscle, 559–561
Calcineurin, immunophilins and, 644
Calcium
cytosolic
activation of renal vascular smooth muscle cell contraction, 428–430
cellular response to sweet taste, 732–733
in *Drosophila* learning, 308
extracellular, in malignant hyperthermia, 577–578
intracellular free Ca^{2+} concentration, regulation, 968–974. *See also* Smooth muscle contraction
growth hormone and, 1098–1099
luminal, ryanodine receptor activation state and, 1041
myoplasmic, in malignant hyperthermia-susceptible and normal skeletal muscle, 542–544
regulation
in central core disease, 572
defects, in other tissues, 579–580
in skeletal muscle, 540–542
defects. *See* Malignant hyperthermia
sarcoplasmic reticulum release. *See* Sarcoplasmic reticulum, calcium release
sarcoplasmic reticulum uptake and storage, in malignant hyperthermia-susceptible pigs, 545–546
sensitivity of myofibrillar apparatus, 405–406
troponin and tropomyosin isoforms and, 406–407
sensitivity of myofilaments
in malignant hyperthermia-susceptible humans, 567
in malignant hyperthermia-susceptible muscle, volatile anesthetics and, 573

in malignant hyperthermia-susceptible pigs, 545
in spinal cord injury, 322–323
in transferrin-independent iron transport system, 37
transport
in MHS human muscle, 571
in MHS pig muscle, 561
mitochondrial, in MHS pig muscle, 563
sarcolemmal surface membranes
in MHS muscle, volatile anesthetics and, 577
in MHS pig muscle, 561
sarcoplasmic reticulum, in MHS muscle, volatile anesthetics and, 573–574

Calcium microelectrodes, myoplasmic calcium determination, 542–543

Calcium release channels, FK506 binding protein interactions, 636–643

Caldesmon
binding to other proteins, 986–987
breast myoepithelial cell expression, 76–77
inhibition of actomyosin ATPase and of thin filament in vitro motility, 987–988
in vivo function, 988–989
presence in thin filaments and cellular localization, 988
smooth muscle contraction, 984, 986–989
inhibition of actomyosin ATPase and of thin filament in vitro motility, 987–988

Calmodulin
in *Drosophila* learning, 308
ryanodine receptor activation state and, 1043–1044
ryanodine receptor activity, 556–557

Calponin
binding to other proteins, 989–990
breast myoepithelial cell expression, 76–77
inhibition of actomyosin ATPase and of thin filament in vitro motility, 990–991
in vivo function, 991–992
presence in thin filaments and cellular localization, 991
in smooth muscle contraction, 984–985, 989–992
inhibition of actomyosin ATPase and of thin filament in vitro motility, 990–991

cAMP. *See* Adenosine 3′,5′-cyclic monophosphate

CapZ protein, in sarcomeric muscle, 382

Carbohydrates, in insulin-regulated gene expression, 1138–1139

Carboxyl-reactive agents, sodium channel permeation path, 901

Cardiac potassium channels, 49–62
ATP-regulated K^+ channels, 60–61
conclusions and future directions, 62
correlation of cloned K^+ channels with endogenous cardiac currents, 55–57
immunodetection of cloned cardiac K^+ channel expression, 56–57
gene defects, lethal arrhythmias and, 61–62
G protein-regulated K^+ channels, 60
heterologous expression of cloned K^+ channels, 54–55
coexpression of human Kvβ_3 subunit with cardiac Kv1.5 α-subunit, 55
functional analysis of cloned K^+ channel α-subunits, 54–55
immunodetection of cloned cardiac K^+ channel expression, 56–57
inward rectifier K^+ channels, 60
I_{sK} protein, molecular physiology, 58–60
molecular physiology of inward rectifier-like K^+ channels, 60–61
molecular physiology of I_{sK} protein, 58–60
I_{sK} and endogenous I_{Ks} current, 60
I_{sK} channel formation or modulation of endogenous channel activity, 59–60
regulation of expression, 57–58
Shaker-like K^+ channel cDNA from mammalian myocardium, 50–54
chromosomal localization of cloned *Shaker*-like α- and β-subunits, 53–54
cloning of cardiac K^+ channel α-subunits, 50–51
cloning of cardiac K^+ channel β-subunits, 51–53

Cardiomyopathy, familial hypertrophic, 387–388

Cardiovascular control interactions, 193–225
arterial baroreceptors, 200–202
conclusion, 224–225
in heart failure, 223–224
in hypertension, 221–222
interplay between reflex regulation and local control, 206–215
interactions between autoregulation and central control, 214–215
interactions between vasopressin and CNS formations controlling blood pressure, 210–211
interactions of adenosine, 214
interactions of angiotensin II, 212–214
nitric oxide interactions as a central neurotransmitter, 207–209
nitric oxide interactions as a peripheral neurotransmitter, 210
peripheral cardiovascular reflexes and vasopressin interactions, 211–212
short-term blood pressure control, arterial baroreceptors-nitric oxid interaction, 206–207
local control interactions, 197–199
endothelial factors, 197–199
myogenic control, 199
methods for constituting interactions and possible pitfalls, 194–197
selectivity and specificity, 194–195
spectrum analysis and nonlinear dynamics, 195–197
in myocardial ischemia, 222–223
in pathophysiological states, 221–224
physical stress, mental stress, and exercise and, 216–218
postural, barometric, and gravitational changes and, 215–216
reflex interactions, 199–206
arterial baroreceptors, 200–202
cardiac receptors, 202–203
central interactions, 204–206
pulmonary receptors and chemoreceptors, 203–204
special physiological conditions, 215–221
aging, 220–221
blood gases and altitude, 218–220
physical stress, mental stress, and exercise and, 216–218
postural, barometric, and gravitational changes, 215–216
pregnancy, 220

Cardiovascular system

cardiac potassium channels. *See* Cardiac potassium channels
control mechanisms and their interactions, 193–225. *See also* Cardiovascular control interactions
Carnitine palmitoyltransferase deficiency, in MHS human muscle, 572
Carotid body, oxygen sensing studies, 860
β-Casein, insulin regulation of expression, 1128
Caveolae
glycosyl phosphoinositol-anchored proteins in, 271–273
smooth muscle cell, ultrastructure, 972
Cell death
insulin-like growth factor action, 1017
in spinal cord injury, physiological relevance, 327
Cellular proliferation
insulin-like growth factors and receptors in, 1016
osteoblasts. *See* Osteoblast differentiation
Central core disease, 565
calcium regulation in, 572
Central nervous system
in cardiovascular reflex control, 204–206
development, differentiation, and cell death, insulin-like growth factor action, 1017
embryonic tissue transplantation, in adult spinal cord injury, neurite growth, 336–337
in malignant hyperthermia, 580
parathyroid hormone-related protein in, 151–152
transplants of embryonic tissue, in adult spinal cord injury, 336
c-*fos*, insulin regulation of expression, 1113–1114
Chemoreceptors, pulmonary, cardiovascular control, 203–204
Choroid plexus, parathyroid hormone-related protein in, 164
Chroion, parathyroid hormone-related protein in, 153
Chromogranins, 774–775
cDNA organization, 775
expression and physiological functions in stomach, 783–784
genomic organization, 775
physiological regulation in enterochromaffin-like cells, 775
posttranslational processing. *See* Gastric endocrine cells
Cleaning reflex, *Drosophila*, habituation, 315
***Clione* spp.,** swim pattern generators, 695–697
Cloning, taste cells, salty taste reception, 743
Colony stimulating factor-1
hematopoiesis in *op/op* mouse, 934–935
macrophage scavenger receptor expression in atherosclerosis, 941–942
recombinant, in vivo administration to *op/op* mouse, 935–936
Color discrimination learning, *Drosophila*, 313
Comparative physiology, nuclear magnetic resonance spectroscopy in. *See* Magnetic resonance spectroscopy
Connectin (titin), in sarcomeric muscle, 380
Copper metabolism, iron metabolism and, 41–42
Cord blood, parathyroid hormone-related protein in, 155
Coronary artery(ies), parathyroid hormone-related protein in, 148
Courtship, *Drosophila*
conditioned courtship with immature males, 315
conditioned courtship with mature females, 314
C protein, in sarcomeric muscle, 379
δ-Crystallin gene, insulin regulation of expression, 1116
Culture studies
breast cancer
models of cellular conversion and origin of cancer in culture, 94–96
models of human breast cancer cells in culture, 96–99
fibroblasts, breast, 81–82
intestinal-derived cells, transferrin-independent iron transport in, 39–40
normal breast epithelial cells, 77–81
vascular smooth muscle cells
aortic, 84–85
breast, 85–86
Cyclooxygenase metabolites
effects on renal metabolism, receptors, and signal transduction, 487–489
renal vascular actions, 489–490
Cyclophilins, 632–634
Cysteine string protein, in synaptic vesicle docking and fusion, 12
Cytochrome-*c* oxidase, aerobic energy production in yeast, 851–852
Cytochrome *P*-450 metabolites
renal metabolism and, 491
renal vascular actions of epoxygenase metabolites, 492
renal vascular actions of ω-hydroxylase metabolites, 491–492
Cytokeratins, breast
luminal epithelial cell expression, 73
myoepithelial cell expression, 73–74
Cytokine(s), macrophage system regulation in *op/op* mouse. *See* Macrophage system, in *op/op* mouse
Cytoskeleton
epithelial cell polarity, 252
actin-based cytoskeleton, 262–267
microtubules, 252–262
proteins, smooth muscle contraction, 992
synaptic vesicle associations, 5–6

D

Demyelination, in spinal cord injury, physiological relevance, 329
Dermis, parathyroid hormone-related protein in, 136–138
Dexamethasone, osteoblast phenotype development, 599
Diabetes mellitus, non-insulin-dependent
GLUT-2 and glucokinase gene expression in, 1140
GLUT-4 glucose transporter gene expression in, 1141–1142
phospho*enol*pyruvate carboxykinase and hexokinase II gene expression in, 1140–1141
potential gene expression defects, 1139–1143
Rad and G_i expression in, 1143
tumor necrosis factor-α and PC-1 gene expression in, 1142–1143
Dihydropyridine receptor, in MHS muscle, 561–562
volatile anesthetics and, 577
***Drosophila* learning assays,** 313–315
acoustic sensitization, 314

arena platform reward learning, 314
color discrimination learning, 313
conditioned courtship with immature males, 315
conditioned courtship with mature females, 314
flight orientation learning, 315
habituation of cleaning reflex, 315
habituation of landing response, 314
larval olfactory conditioning, 314
leg positioning conditioning, 314
olfactory classical conditioning, 313
operant olfactory avoidance learning, 313
proboscis extension reflex
habituation, 314
Pavlovian conditioning, 314
sensitization, 314
sucrose reward learning, 313
***Drosophila* learning mutants,** 299–315
amnesiac (*amn*) mutant, 307
biochemical alterations, 305–310
calcium/calmodulin-dependent protein kinase, 308
learning mutants affecting cAMP signaling, 305–307
learning mutants affecting neuropeptide function and expression, 307
learning mutants affecting neurotransmitter biosynthesis, 308
learning mutants affecting protein kinase C, 307–308
mutants in ion channels, 308–309
other mutants, 309
conditioning mutants, 302–305
dopa decarboxylase (*Ddc*) mutant, 308
dunce (*dnc*) mutants, 305–306
eag mutant, 308
neuromuscular junction, facilitation and posttetanic potentiation at, 312
physiological alterations, 310–312
facilitation and posttetanic potentiation at neuromuscular junction, 312
physiological properties of isolated mushroom body neurons, 310–311
response properties and oscillations in mushroom body neurons, 311–312
protein kinase A (*DCO*) mutant, 306–307
rutabaga (*rut*) mutants, 306
Shaker (Sh^5) mutant, 308
structural brain mutants, 300–302
summary, 312–313
turnip (*tur*) mutant, 307–308

E

E2A basic helix-loop-helix protein(s), molecular adaptation to hypoxia, 865
Ear muscles, myofibrillar protein isoforms, 384
Edema, in spinal cord injury, 322
Electric taste, 751–753
Electrolyte(s), in tubuloglomerular feedback mechanism, 449
Electrophysiology, salty taste reception, 740–741
Embryology, parathyroid hormone-related protein in, 133–136
Emotional stress, cardiovascular control interactions in, 218
Endocrine system, parathyroid hormone-related protein in, 158–162
Endocytosis
nerve terminals, 6–7
protein toxins, 951–953
thyrotropin-releasing hormone receptors, 184–185
in transferrin-independent iron transport system, 37
Endoplasmic reticulum, protein toxin transport to, 956–958
Endothelial cell(s), breast, 86
Endothelial factors
cardiovascular control, 197–199
nitric oxide. *See* Nitric oxide
paracrine regulation of renal microvasculature, 433–443. *See also* Renal microcirculation, endothelial-derived paracrine influences
Endothelin(s), 440–441
cardiovascular control, 197–199
cellular mechanisms of action, 442–443
effects on renal hemodynamics, 441
effects on renal microcirculation, 441–442
interactions with other vasoactive factors, 442
receptors, 440–441
Energy metabolism
alkylphosphonates in, nuclear magnetic resonance spectroscopy, 827–828
environmental factors and, 801–814. *See also* Magnetic resonance spectroscopy
exercise and, nuclear magnetic resonance spectroscopy, 814–820. *See also* Magnetic resonance spectroscopy
growth and development and, nuclear magnetic resonance spectroscopy, 820–821
parasitism and, nuclear magnetic resonance spectroscopy, 821–822
phosphagens in, nuclear magnetic resonance spectroscopy, 822–824
phosphodiesters in, nuclear magnetic resonance spectroscopy, 825–827
tyrosine-*O*-phosphate in, 828
unusual compounds in, nuclear magnetic resonance spectroscopy, 824–829
in yeast, oxygen adaptation and, 851–852
Enteric bacteria, oxidative stress, 845–846
Enterochromaffin cells, serotonin, 788
Enterochromaffin-like cells
chromogranin A gene expression, 775
histidine decarboxylase gene expression, 774
secretory products, 785–786
Environmental factors, energy metabolism and, 801–814. *See also* Magnetic resonance spectroscopy
Enzyme(s)
gluconeogenesis, hypoxic induction, 874–875
glycolytic, hypoxic induction, 873–874
kinetics of enzyme reactions in living systems, magnetic resonance spectroscopy, 829–830
muscle fiber surface membranes, in malignant hyperthermia-susceptible humans, 571

Epidermis, parathyroid hormone-related protein in, 136–138
Episialin, breast epithelial cell expression, 72
Epithelial cells
breast, 71–73
polarity
actin-based cytoskeleton and, 262–267
microtubules and, 252–262
tight junctions, 247–251
renal. *See* Kidney epithelium
tight junctions, 247–251
Erythrocyte(s), in malignant hyperthermia, 579
Erythropoietin
hypoxic induction, 867–870
gene regulation, 868–870
sites of production, 867–868
oxygen sensing studies, 859–860
Escherichia coli, respiratory systems, 841–845
control of respiratory protein gene expression, 842–843
effects of nitrate, 843
effects of oxygen, 842–843
pathways, 841–842
transcription networks, 843–845
Arc network, 843–844
combinatorial regulation, 845
Fnr, 844–845
Estrogen receptor(s)
breast epithelial cell expression, 72–73
insulin regulation of gene expression, 1129
Eukaryotes, iron uptake in, 31–43. *See also* Iron uptake
Excitotoxins, in spinal cord injury, 323
Exercise
cardiovascular control interactions in, 216–217
energy metabolism and, 814–820. *See also* Magnetic resonance spectroscopy
Exo 1, in synaptic vesicle docking and fusion, 16
Extracellular matrix
in breast cancer, 99–100
control of osteoblast proliferation and differentiation, 598
Eye muscles, myofibrillar protein isoforms, 384

F

Familial hypertrophic cardiomyopathy, 387–388
Fatigue, skeletal muscle, resistance to, 409–410
Fatty acids, ryanodine receptor activity, 556
Fatty-acid synthase gene, insulin regulation of expression, 1116–1117
Ferrireductases
in iron transport, 34–36
in yeast, 36
Fibroblast(s), breast, 81–82
Fish, regeneration of spinal pathways in lesioned spinal cords, 332–333
FK506 binding proteins, 634–636
calcium release channels and, 636–643
inositol 1,4,5-trisphosphate receptors and, 643
ryanodine receptors and, 637–643
transforming growth factor-β receptor interactions, 643
Flight orientation learning, *Drosophila,* 315
Fluid and electrolyte homeostasis, protein trafficking and polarity in kidney epithelium, 245–288. *See also* Kidney epithelium
Fura 2, myoplasmic calcium determination, 543

G

GAP-43, in synaptic vesicle docking and fusion, 14–15
Gastric endocrine cells, 767–789
amines and other active products, 785–788
chromogranin processing, 784
enterochromaffin cells, secretory products, 788
enterochromaffin-like cells, secretory products, 785–786
functional control of gene expression, 769–775
amine transporters, 775
chromogranins, 774–775
gastrin gene, 769–771
histidine decarboxylase, 773–774
somatostatin gene, 771–773
gastric endocrine system organization, 768–769
gastrin gene expression, 769–771
cDNA sequences, 769
cell-specific expression, 769–771
genomic organization, 769
physiological modulation, 771
in transfected cell lines, 771
gastrin processing, 776–782
amidation, 779–780
gene products and their biological properties, 776–777
phosphorylation, 780–781
progastrin cleavage, 779
cell-specific patterns, 781–782
secretory pathway in G cells, 777–778
sufation, 780
in transfected cell lines, 781
G cells
γ-aminobutyric acid, 787–788
luminal amines, 786–787
secretory granule amines, 787
secretory products, 786–788
histidine decarboxylase gene expression, 773–774
cDNA sequence, 773–774
cell-specific expression, 774
genomic organization, 774
physiological regulation of expression in enterochromaffin-like cells, 774
perspectives, 788–789
posttranslational processing of secretory products, 775–785
chromogranins, 783–784
gastrin, 776–782

other peptides, 784–785
secretory pathway, 775–776
somatostatin, 782–783
secretory pathway, 775–776
processing, 776
progression and sorting, 775–776
serotonin, 788
somatostatin gene expression, 771–773
cDNA sequences, 771–772
cell-specific expression, 772
genomic organization, 772
physiological regulation, 772–773
antral D cells, 772–773
corpus D cells, 773
somatostatin processing, 782–783
gene products and their biological properties, 782
pathways, 782–783
prosomatostatin processing, 783

Gastrin
biological properties, 776–777
gene. *See* Gastrin gene
posttranslational processing. *See* Gastric endocrine cells

Gastrin cells. *See* G cells

Gastrin gene
cDNA sequences, 769
expression
cell-specific, 769–771
gastric endocrine cell control, 769–771
physiological modulation, 771
in transfected cell lines, 771
genomic organization, 769

Gastrointestinal tract
bacteria, oxidative stress, 845–846
endocrine system. *See* Gastric endocrine cells
gastric rhythm, 699–701
parathyroid hormone-related protein in, 143–144

G cells
γ-aminobutyric acid, 787–788
luminal amines, 786–787
secretory granule amines, 787
secretory pathway, 777–778
secretory products, 786–788

Gene(s)
anaerobic, in yeast, 854–856
cardiac potassium channel, defects, lethal arrhythmias and, 61–62
chromogranins, 775
gastrin, 769–771
glucose metabolism, hypoxic induction, 872–875
histidine decarboxylase, 773–774
histone genes, in proliferating osteoblasts, 600–605
hypoxic, in yeast, 856–857
insulin regulation of expression, 1109–1146. *See also* Insulin; *specific genes*
iron metabolism in eukaryotes, 33
osteocalcin, in postproliferative osteoblasts, 605–612
parathyroid hormone-related protein, 129
RYR expression in different tissues, 579
somatostatin, 771–773
thyrotropin-releasing hormone receptor, 175–177

Glucagon gene, insulin regulation of expression, 1126–1127

Glucocorticoid receptor, insulin regulation of gene expression, 1129

Glucocorticoid responsive element, osteocalcin gene, 610–611

Glucokinase gene, expression in non-insulin-dependent diabetes mellitus, 1140

Glucose metabolism, in hypoxia
gluconeogenesis enzyme gene expression, 874–875
glucose transporter-1 (GLUT-1) induction, 872–873
glycolytic enzyme gene expression, 873–874

Glucose transporter(s)
GLUT-1 gene
hypoxic induction, 872–873
insulin regulation of expression, 1119–1120
GLUT-2 gene, expression in non-insulin-dependent diabetes mellitus, 1140
GLUT-4 gene, expression in non-insulin-dependent diabetes mellitus, 1141–1142

L-Glutamate, taste receptors (sensing), 735. *See also* Taste reception, umami

Glyceraldehyde-3-phosphate dehydrogenase gene, insulin regulation of expression, 1112–1113

Glycoprotein 330, in proximal renal tubule, 278
targeting, 270

Glycosyl phosphoinositol anchor, 270

Golgi apparatus, protein toxin transport to, 953–955

G protein(s)
in bitter taste, 737
cardiac potassium channel regulation, 61
G_i expression in non-insulin-dependent diabetes mellitus, 1143
in protein trafficking and targeting, 275–277
heterotrimeric G proteins, 275–276
monomeric G proteins, 276–277
sweet response, 730–731
thyrotropin-releasing hormone receptor coupling, 181–183

Granulocyte macrophage-colony stimulating factor, in breast cancer, 104

Growth and development
energy metabolism and, nuclear magnetic resonance spectroscopy, 820–821
insulin-like growth factors and receptors in, 1014–1016

Growth hormone gene, insulin regulation of expression, 1128

Growth hormone receptor, 1090–1093
cytokine/hematopoietin receptor superfamily, 1091–1093
growth hormone binding and receptor dimerization, 1090–1091
growth hormone-dependent tyrosyl phosphorylation of, 1095

Growth hormone signaling, 1089–1101
activation of JAK2 tyrosine kinase, 1093–1095
activation of mitogen-activated protein kinase signaling pathway by growth hormone, 1095–1096
activation of Stat family proteins, 1099–1100
conclusions, 1100–1101

cytokine/hematopoietin receptor superfamily, 1091–1093
growth hormone binding and receptor dimerization, 1090–1091
growth hormone-dependent tyrosyl phosphorylation of growth hormone receptor and JAK2, 1095
growth hormone receptor, 1090–1093
protein kinase C in, 1097–1098
regulation of intracellular calcium and nitric oxide synthase by growth hormone, 1098–1099
utilization of insulin receptor substrates 1 and 2 and phosphatidylinositol 3′-kinase, 1096–1097
Guanidinium toxins, sodium channel probes, 900–901
Guanosine 3′,5′-cyclic monophosphate (cGMP), renal vascular control, 430
Guanosine triphosphate binding proteins, in smooth muscle contraction, 984
Gustducin, in bitter taste, 737

H

Hair follicles, parathyroid hormone-related protein in, 136–138
Halothane, actions in MHS muscle, 573–579
calcium sensitivity of myofilaments, 573
conclusions, 578–579
membrane lipid motion, 578
muscle fiber bundles, 576–577
conclusions, 577
contractile activity of muscle bundles, 577
electrophysiology, 576–577
sarcolemma and transverse tubules, 577–578
Ca^{2+} transport and permeability, 577
conclusions, 578
dihydropyridine receptor activity, 577
role of extracellular Ca^{2+}, 577–578
sarcoplasmic reticulum calcium release, 574–576
Ca^{2+} dependence of Ca^{2+} release in single muscle fibers, 575
conclusions, 576
kinetics, 574
passive Ca^{2+} permeability of SR vesicles, 574–575
ryanodine receptor single-channel activities, 575–576
thresholds for initiation, 574
sarcoplasmic reticulum calcium transport, 573–574
Halothane testing, pigs, malignant hyperthermia susceptibility, 540
Heart
in malignant hyperthermia, 579
parathyroid hormone-related protein in, 146–148
potassium channels. *See* Cardiac potassium channels
ryanodine receptor distribution in cardiac muscle, 1036–1037
sodium channels. *See* Sodium channel(s), cardiac and nerve channels
Heart failure, cardiovascular control interactions in, 223–224
Heat shock proteins/factor, molecular adaptation to hypoxia, 865
Heat stress, cardiovascular control interactions in, 217–218
Hematopoiesis, in *op/op* mouse, colony stimulating factor-1 in, 934–935
Heme biosynthesis, bacterial, 849–850
Heme protein, in oxygen sensing, 859–860
Hemochromatosis, hereditary, 33–34
Hemoglobin, bacterial, 848–849
Hepatobiliary system, parathyroid hormone-related protein in, 151
Hepatocyte(s), in MHS pigs, 580
Hereditary disorders
congenital hypotransferrinemia, 33
copper metabolism, 41–42
hemochromatosis, 33–34
Hexokinase II gene, expression in non-insulin-dependent diabetes mellitus, 1140–1141
H fibers, salty taste reception, 745
Histamine, enterochromaffin-like cells, 785–786
Histidine decarboxylase gene, 773–774
cDNA sequences, 773–774
cell-specific expression, 774
genomic organization, 774
physiological regulation of expression in enterochromaffin-like cells, 774
Histone genes, in proliferating osteoblasts, 600–605
nuclear structure and, 613–614
posttranscriptional control, 601
regulation of transcription, 602–603
transcriptional control, 601
Hormone(s), salty taste reception, 747–748
Hormone receptors, proximal renal tubule, 278
H protein, in sarcomeric muscle, 379
Hypercalcemia, of malignancy, 128. *See also* Parathyroid hormone-related protein
Hypercapnia
cardiovascular control interactions and, 219–220
energy metabolism and, 809–810
Hypertension, cardiovascular control interactions in, 221–222
Hyperthermia, malignant. *See* Malignant hyperthermia
Hypertriglyceridemia
apolipoprotein CIII in, 1145
potential gene expression defects, 1143–1145
Hypoglycemia, tumor-associated, insulin-like growth factor II and, 1019
Hypometabolism, environmental challenge and, 812–813
Hypotransferrinemia, congenital, 33
Hypoxia
cardiovascular control interactions and, 218–220
environmental, energy metabolism in vertebrates and, 801–804
erythropoietin (Epo) production, 867–870
gene regulation, 868–870
3′-enhancer, 868–869
promoter, 869
RNA stability, 869–870
role of nuclear receptors, 869
sites of, 867–868
glucose metabolism
gluconeogenesis enzyme gene expression, 874–875
glucose transporter-1 (GLUT-1) induction, 872–873

glycolytic enzyme gene expression, 873–874
induction of physiologically relevant genes, 867–875
erythropoietin (Epo), 867–870
genes in glucose metabolism, 872–875
tyrosine hydroxylase (TH) activation, 870–871
vascular endothelial growth factor, 871–872
local
energy metabolism in invertebrates and, 808–809
energy metabolism in vertebrates and, 806–808
molecular adaptation, 839–875
current and future challenges, 875
hypoxic induction of physiologically relevant genes, 867–875
multicellular organisms, 858–875
oxygen sensing, 858–863. *See also* Oxygen sensing
signal transduction, 863–867
unicellular organisms, 840–858
signal transduction, 863–867
hypoxia inducible factor-1, 865–867
protein phosphorylation, 863–864
redox modification of transcription factors, 864–865
AP-1 transcription factors, 864–865
E2A basic helix-loop-helix proteins, 865
heat shock proteins and heat shock factor, 865
NFκB, 865
tyrosine hydroxylase (TH) activation, 870–871
animal studies, 870
regulation of mRNA stability, 870–871
transcriptional regulation, 870
vascular endothelial growth factor expression, 871–872
mRNA expression, 871
regulation of mRNA stability, 872
transcriptional regulation, 871–872
Hypoxia inducible factor-1, molecular adaptation to hypoxia, 865–867

I

Immune system, parathyroid hormone-related protein in, 163
Immunohistochemistry, salty taste reception, 741–743
Immunophilins, 631–644
calcineurin and, 644
conclusions, 644
cyclophilins, 632–634
FK506 binding proteins, 634–636
calcium release channels and, 636–643
inositol 1,4,5-trisphosphate receptors and, 643
ryanodine receptors and, 637–643
transforming growth factor-β receptor interactions, 643
overview, 631–636
prolyl isomerase activity, 636
Immunotoxins, 959–960
Inflammatory response, in spinal cord injury, 323
physiological relevance of cellular processes at lesion site, 327–329
Inositol 1,4,5-trisphosphate
bitter response, 738
calcium release from sarcoplasmic reticulum in vertebrate skeletal muscle, 1040
sweet response, 731
Inositol 1,4,5-trisphosphate receptor(s), FK506 binding proteins and, 643
In situ hybridization, taste cells, salty taste reception, 743–744
Insulin
mechanism of action on gene transcription, 1129–1137
miscellaneous factors, 1136–1137
mitogen-activated protein kinase pathway, 1130–1134
AP-1 motif, 1132–1134
nuclear factor κB, 1134
serum response element, 1131–1132
nuclear tyrosine kinases in, 1136
phosphatidylinositol 3′-kinase pathway, 1134–1135
protein kinase C in, 1135–1136
regulation of gene expression, 1109–1146
acetyl-CoA carboxylase, 116
α-acid glycoprotein, 1120–1121
α-amylase, 1117
apolipoprotein gene family, 1143–1144
carbohydrates and other metabolites in, 1138–1139
β-casein, 1128
c-*fos*, 1113–1114
conclusions, 1145–1146
δ-crystallin, 1116
estrogen and glucocorticoid receptors, 1129
fatty-acid synthase, 1116–1117
general considerations, 1110–1112
glucagon, 1126–1127
GLUT-1 glucose transporter, 1119–1120
glyceraldehyde-3-phosphate dehydrogenase, 1112–1113
identification of negative insulin response sequences, 1121–1129
identification of positive insulin response sequences, 1112–1121
insulin-like growth factor binding protein-1, 1124–1125
insulin receptor and insulin receptor substrate-1, 1129
malic enzyme and growth hormone, 1128
mechanism of action on gene transcription, 1129–1137
microsomal triglyceride transfer protein large subunit, 1127
miscellaneous genes, 1127–1129
neuropeptide Y, 1127–1128
phospho*enol*pyruvate carboxykinase, 1121–1124
potential gene expression defects in hypertriglyceridemia, 1143–1145
potential gene expression defects in NIDDM, 1139–1143
prolactin, 1114–1116
through AP-1 motif, 1120
thyroglobulin, 1118
thyroperoxidase, 1118–1119
thyrotropin receptor, 1119
tyrosine aminotransferase, 1125–1126
regulation of mRNA stability, 1137
regulation of mRNA translation, 1137–1138
Insulin-like growth factor(s), 1005–1020

in breast cancer, 105
historical overview, 1006
mediators. *See* Insulin-like growth factor receptors
physiological actions, 1014–1016
in bone, 1017
in cancer, 1018–1019
cell death prevention, 1018
cellular proliferation, 1016
development, differentiation, and cell death, 1016–1018
embryonic and fetal growth, 1015–1016
in nervous system, 1017–1018
postnatal growth, 1014–1015
in skeletal muscle, 1016–1017
in skin, 1017
somatic growth and, 1014–1016
summary and perspectives on future research, 1019–1020
tumor hypoglycemia, 1019
Insulin-like growth factor binding protein(s), 1013–1014
functions, 1013–1014
IGFBP-1 gene, insulin regulation of expression, 1124–1125
IGFBP-3, antineoplastic properties, 1019
structural considerations, 1013
Insulin-like growth factor receptors
in embryonic and fetal growth, 1015–1016
historical overview, 1006
IGF-I, 1006–1011
in embryonic and fetal growth, 1015–1016
role in signaling pathways activated by other growth factors, hormones, and oncogenes, 1010–1011
signal transduction through, 1007–1008
structural considerations, 1006–1007
structure-function relationships, 1008–1010
in tumorigenesis, 1018
IGF-II, 1011–1013
in embryonic and fetal growth, 1015
function, 1012
in neoplastic transformation, 1019
structural considerations, 1011–1012
Structure-function relationships, 1012–1013
Insulin receptor, in growth hormone signaling, 1096–1097
Insulin receptor gene, insulin regulation of expression, 1129
Insulin receptor substrate-I gene, insulin regulation of expression, 1129
Intercalated cells, renal collecting duct, 283–287
Interleukin(s), IL-6, in breast cancer, 105
Interstitial fluid, adenosine concentrations, 472–473
Intestine(s)
parathyroid hormone-related protein in, 143–144
small, transferrin-independent iron transport in, 39–40
Ion channels
Drosophila learning mutants, 308
muscle fiber surface membranes, in malignant hyperthermia-susceptible humans, 571
in taste reception, 726
Iron metabolism, copper metabolism and, 41–42
Iron uptake, 31–43
conclusions, 42–43
inherited disorders, 33–34
congenital hypotransferrinemia, 33
hereditary hemochromatosis, 33–34
iron transport systems in yeast, 40–41
high-affinity transport systems, 40
low-affinity transport systems, 40–41
mechanisms of iron assimilation in mammalian cells, transferrin and transferrin receptors, 32–33
transferrin and transferrin receptors, 32–33
transferrin-independent, 34–36
ferrireductases in iron transport, 34–36
transferrin-independent iron transport system, 36–38
calcium dependence, 37
endocytosis and, 37
metal competition, 37
regulation of, 37–38
in reticulocytes, 38–39
in small intestine and intestinal-derived culture cells, 39–40
in specialized cell types, 38–40
transport mechanisms, 33
Ischemia
local
energy metabolism in invertebrates and, 808–809
energy metabolism in vertebrates and, 806–808
myocardial, cardiovascular control interactions in, 222–223
renal, protein trafficking and epithelial cell polarity in, 288
in spinal cord injury, 322

K

Kallikrein-kinin system
kinin-mediated component of renal vascular responses to ACE inhibitors, 462–463
in renal vascular control, 453–456. *See also* Bradykinin
kinins and medullary circulation, 502–503
Kidney
arachidonic acid metabolite formation and relative prominence in, 485–487
collecting duct
microtubule function, 260–262
proton pumps in intercalated cells, 283–287
tight junctions, 251
water channels in principal cells, 281–283
aquaporins in, 281–283
water channel recycling, 281
distal convoluted tubule, tight junctions, 251
ischemia, protein trafficking and epithelial cell polarity in, 288
microvascular function, paracrine regulation. *See* Renal microcirculation
parathyroid hormone-related protein in, 149–151
proximal tubule
glycoprotein gp330, 278

glycoprotein gp330 targeting, 270
microtubule function, 258–260
polarized targeting of membrane proteins, 277–280
polypeptide hormone receptors, 278
proton ATPase, 279
sodium-hydrogen exchanger, 278–279
tight junctions, 251
water channels, 279–280
thick ascending limbs of Henle, tight junctions, 251
thin limbs of Henle
polarized targeting of membrane proteins, 280
tight junctions, 251
vasculature, paracrine regulation. *See* Renal microcirculation
visceral epithelial cells, tight junctions, 251–252
Kidney disease, protein trafficking and epithelial cell polarity in, 288
Kidney epithelium
actin-based cytoskeleton in, 262–267
cell polarity, 245–247
actin-based cytoskeleton in, 262–267
cell-cell contacts, 264–266
in disease, 287–288
membrane-associated cytoskeleton, 263–264
microtubules and, 252–262
in polycystic kidney disease, 287
in renal ischemia, 288
tight junctions and, 247–252
water channels, 283
polarized secretion in, 287
polarized targeting of membrane proteins, 277–287
collecting duct, 281–287
proximal tubule, 277–280
sodium-potassium-ATPase, 280–281
thin limbs of Henle, 280
protein trafficking
actin-based cytoskeleton in, 266–267
collecting duct, 281–287
proton pumps in intercalated cells, 283–287
water channels in principal cells, 281–283
G proteins in, 275–277
microtubules in, 258–262
polarized secretion, 287
polarized targeting of membrane proteins, 277–287
protein sorting and trafficking pathways, 267–277
proximal tubule, 277–280
gp330, 278
polypeptide hormone receptors, 278
proton-ATPase, 279
sodium/hydrogen exchanger, 278–279
water channels, 279–280
sodium-potassium-ATPase in, 280–281
sorting signals on proteins, 268–273
apical targeting signals, 270
basolateral and endocytotic sorting signals, 269–270
glycoprotein gp330 targeting in proximal tubule, 270
glycosyl phosphatidylinositol (GPI) anchor, 270
GPI-anchored proteins, 270
GPI-anchored proteins in caveolae, 271–273
GPI-anchored proteins in kidney, 273
lysosomal hydrolase sorting, 269
thin limbs of Henle, 280
transport vesicles, 273–277
vesicle budding, 274–275
vesicle fusion, 275
tight junctions, 247–252. *See also* Tight junctions
Kinins. *See* Kallikrein-kinin system

L

Lamprey, rhythmic motor pattern generation, 702–704
Landing response, *Drosophila*, habituation, 314
Larval olfactory conditioning, *Drosophila*, 314
Laryngeal muscles, myofibrillar protein isoforms, 384
Learning
definition, 302
in *Drosophila*
assays, 313–315. *See also Drosophila* learning assays
calcium/calmodulin-dependent protein kinase in, 308
model for biochemistry underlying, 309–310
Leech, rhythmic motor pattern generation
heartbeat, 697–698
intersegmental coordination, 704–705
Leg position conditioning, *Drosophila*, 314
Lipase activity
in MHS human muscle tissue, 571–572
in MHS pig muscle tissue, 564
Lipid(s)
in MHS human muscle tissue, 571–572
in MHS pig muscle tissue, 564
Lipoxygenase metabolites
renal metabolism, receptors, and signal transduction, 490
renal vascular actions, 490–491
Liver. *See* Hepatobiliary system
Lung
parathyroid hormone-related protein in, 148–149
receptors and chemoreceptors, cardiovascular control, 203–204
Lymphocyte(s)
in malignant hyperthermia, 579–580
parathyroid hormone-related protein in, 163

M

Macrophage(s). *See also* Macrophage system
breast, 89
in spinal cord injury, 328–329
Macrophage system
in atherosclerosis, 941–942
cell types and differentiation stages, 927–928

colony stimulating factor-1 and macrophage scavenger receptor expression in atherosclerosis, 941–942
conclusions and future directions, 942–943
cytokine regulation, in *op/op* mouse. *See* Macrophage system, in *op/op* mouse
macrophage production and function
growths factors regulating, 931–932
molecules regulating, 928–931
in *op/op* mouse. *See* Macrophage system, in *op/op* mouse
regulation, macrophage growth factors and activators and, 937–939
in *op/op* mouse, 932–943
colony stimulating factor-1 in hematopoiesis, 934–935
discovery and molecular and cellular caharacterization, 932–934
implications for macrophage heterogeneity, 939–940
in vivo administration of recombinant colony stimulating factor-1 to, 935–936
response to sepsis, experimental tumors, and trauma, 940–941
Macula densa. *See also* Tubuloglomerular feedback mechanism
signaling mechanisms
renin release, adenosine and, 478–479
tubuloglomerular feedback mechanism, 447–448
Magnesium, ryanodine receptor activity, 556
Magnetic resonance spectroscopy
applications in comparative physiology, 799–830
concluding remarks and perspectives, 830
endogenous factors and energy metabolism, 814–822
environmental factors and energy metabolism, 801–814
metabolic pathways in living systems, 822–830
endogenous factors and energy metabolism
development and growth, 820–821
exercise, 814–820
parasitism, 821–822
environmental factors and energy metabolism, 801–814
anesthetics, 813–814
environmental anoxia in invertebrates, 804–806
environmental hypoxia in vertebrates, 801–804
hypercapnia, 809–810
hypometabolism, 812–813
local hypoxia/ischemia in invertebrates, 808–809
local hypoxia/ischemia in vertebrates, 806–808
osmotic and pH stress, 810–812
oxygen availability, 801–809
exercise and energy metabolism, 814–820
conclusions, 820
^{1}H- and ^{13}C-NMR studies on isolated amphibian muscles, 816–817
in vivo ^{31}P-NMR studies on muscle metabolism, 819–820
^{31}P-NMR studies on isolated amphibian muscles, 814–816
^{31}P-NMR studies on isolated invertebrate muscle, 817–819
metabolic pathways in living systems, 822–830
alkylphosphonates, 827–828
enzyme kinetics, 829–830
phosphagens, 822–824
phosphodiesters, 825–827
^{31}P resonances characteristic of microorganisms, 828
seeing the invisible, 828–829
tyrosine-*O*-phosphate, 828
unknown high-energy phosphates, 828
unusual compounds, 824–829
unusual sugar phosphates, 828
Malic enzyme gene, insulin regulation of expression, 1128
Malignancy
breast. *See* Breast cancer
humoral hypercalcemia of, 128. *See also* Parathyroid hormone-related protein
insulin-like growth factors in, 1018–1019
Malignant hyperthermia, 537–581
calcium regulation defects in other tissues, 579–580
cardiac muscle in, 579
erythrocytes, lymphocytes, and hepatocytes in, 579–580
excitation-contraction coupling and calcium regulation in skeletal muscle, 540–542
in humans, 538–540
clinical features, 538–539
genetic analysis, 565–566
genetic heterogeneity, 566
genetic linkage studies and in vitro contracture test, 566
linkage to chromosome 19 and *RYR1*, 565–566
skeletal muscle as site of primary abnormality, 539–540
malignant hyperthermia-susceptible humans
actions of volatile anesthetics, 573–579. *See also* Halothane
caffeine action in, 572–573
conclusions, 573
contractile activity of single fibers, 573
effects of other agents on contractile activity of muscle bundles, 573
[^{3}H]ryanodine binding and single channel activities, 572–573
calcium sensitivity of myofilaments, 567
carnitine palmitoyltransferase deficiency, 572
lipid content and lipase activity, 571–572
mitochondrial respiratory activities and Ca^{2+} transport, 571
muscle contractile properties in situ, 570–571
conclusions, 570–571
kinetics of contractility and force generation, 570
muscle fiber surface membranes, 571
sarcoplasmic reticulum calcium release, 568–570
Ca^{2+} dependence of Ca^{2+} release in single fibers, 568
Ca^{2+} dependence of [^{3}H]ryanodine binding to solubilized ryanodine receptors, 568–569
Ca^{2+} dependence of ryanodine receptor single-channel activity, 569
conclusions, 569–570
luminal Ca^{2+} threshold for Ca^{2+}-induced Ca^{2+} release, 569
sarcoplasmic reticulum calcium uptake and storage, 567–568
skeletal muscle function, 567–573
malignant hyperthermia-susceptible muscle. *See* Muscle, malignant hyperthermia-susceptible
malignant hyperthermia-susceptible pigs
actions of volatile anesthetics, 573–579. *See also* Halothane
antioxidants and free radicals, 565

caffeine action in, 559–561
conclusions, 560–561
contractile activity of single fibers and muscle bundles, 560
ryanodine receptor properties in sarcoplasmic reticulum vesicles and lipid bilayers, 559–560
calcium sensitivity of myofilaments, 545
effects of *RYR1* mutation on sarcoplasmic reticulum and muscle function, 545–561
caffeine action in MHS pig muscle, 559–561
calcium sensitivity of myofilaments, 545
expression of *RYR1* cDNAs in cultured cells, 559
influence of fiber type on ryanodine receptor defect, 558–559
metabolites that interact with ryanodine receptor, 556–557
muscle contractile activity, 553–556
ryanodine receptor properties in heterozygotes, 557–558
sarcoplasmic reticulum Ca^{2+} release, 546–553
sarcoplasmic reticulum Ca^{2+} uptake and storage, 545–546
expression of *RYR1* cDNAs in cultured cells, 559
metabolites that interact with ryanodine receptor, 556–557
calmodulin, 556–557
conclusions, 557
fatty acids and their metabolites, 556
Mg^{2+}, adenine nucleotides, and P_i, 556
pH, 556
mitochondria in, 563–564
Ca^{2+} transport, 563
respiratory activity, 563
muscle changes occurring with development, 562
muscle contractile activity in vivo and in situ, 553–556
conclusions, 555–556
contractile threshold of fiber bundles, 553–554
contraction of muscles in situ, 555
muscle fiber bundle preparations, 553
properties of muscle cell cultures, 555
surface membrane electrophysiology, 555
time course and magnitude of force generation in fiber bundles, 554–555
phosphatidylinositol metabolism, 564–565
ryanodine receptor defect, influence of fiber type on, 558–559
ryanodine receptor properties in heterozygotes, 557–558
sarcolemma and transverse tubules, 561–562
Ca^{2+} transport by surface membranes, 561
dihydropyridine receptors and junctional membrane protein content, 561–562
similarities of purified surface membranes, 561
sarcoplasmic reticulum calcium release, 546–553
Ca^{2+} dependence of Ca^{2+} release in single fibers, 548–549
Ca^{2+} dependence of [^{3}H]ryanodine binding, 549–550
Ca^{2+} dependence of ryanodine receptor single-channel activity, 550–551
conclusions, 551–553
kinetics of Ca^{2+} dependence of Ca^{2+} release, 547–548
luminal Ca^{2+} threshold for Ca^{2+}-induced Ca^{2+} release, 546–547
sarcoplasmic reticulum calcium uptake and calcium storage, 545–546
sarcoplasmic reticulum membrane lipid composition and mobility, 562–563
secondary effects of *RYR1* mutation on muscle, 561–565
antioxidants and free radicals, 565
changes occurring with muscle development, 562
membrane lipid composition and mobility, 562–563
mitochondria, 563–564
phosphatidylinositol metabolism, 564–565
sarcolemma and transverse tubules, 561–562
tissue lipase activity and lipid composition, 564
tissue lipase activity and lipid composition, 564
myoplasmic calcium in susceptible muscle, 542–544
conclusions, 544
determination using fura 2, 543
determination via calcium microelectrodes, 542–543
nervous system in, 580
in pigs, 538–540
clinical features, 538–539
genetic basis, 545
halothane susceptibility testing, 540
RYR1 mutation, Arg615Cys mutation, 545
skeletal muscle as site of primary abnormality, 539–540
porcine *RYR1* mutation, 545
Arg615Cys mutation, 545
effects on sarcoplasmic reticulum and muscle function in malignant hyperthermia-susceptible pigs, 545–561
genetic basis, 545
skeletal muscle as site of primary abnormality, 539–540
metabolic changes in susceptible muscle, 539–540
ultrastructure of susceptible muscle, 540
summary, 580–581
susceptibility testing, 540
contracture testing of muscle biopsies, 540
halothane testing of pigs, 540
Mandibular muscles, myofibrillar protein isoforms, 384
Memory, definition, 302
Menke's disease, 41–42
Mental stress, cardiovascular control interactions in, 218
Merkel-like cells, taste buds, 725
Metals, transferrin-independent iron uptake and, 37
MHS. *See* Malignant hyperthermia, malignant hyperthermia-susceptible
Microsomal triglyceride transfer protein, large subunit, insulin regulation of expression, 1127
Microtubule(s), 252
epithelial cell polarity, 252–262
in kidney epithelial cells, 258–262
collecting duct, 260–262
proximal tubule, 258–260
microtubule motors, 253–256
protein trafficking, 256–258
direct vectorial delivery, 257
indirect delivery, 257
random delivery, 257–258
Mitochondria

in malignant hyperthermia-susceptible humans, 571
in malignant hyperthermia-susceptible pigs, 563–564
in oxygen sensing, 862–863
Mitogen-activated protein kinase
in insulin-regulated gene transcription, 1130–1134
signaling, growth hormone activation, 1095–1096
smooth muscle contraction, 983–984
Molecular biology
cardiac potassium channels, 49–62. *See also* Cardiac potassium channels
myofibrillar proteins. *See* Myofibrillar protein isoforms
parathyroid hormone-related protein, 129–132
thyrotropin-releasing hormone receptor, 175–187
Mononuclear phagocyte system. *See* Macrophage system
Movement, rhythmic. *See* Rhythmic motor pattern generation
M protein, in sarcomeric muscle, 379–380
mRNA
stability, insulin-regulated, 1137
translation, insulin-regulated, 1137–1138
Muscle
calcium sensitivity and regulatory proteins, 405–407
development
changes in MHS pig muscle, 562
patterns of myofibrillar protein isoform expression during, 390–395
development, differentiation, and cell death, insulin-like growth factor action, 1016–1017
excitation-contraction coupling and calcium regulation in, 540–542
force-velocity and body size, 405
force-velocity and myosin isoforms, 400–405
correlations between shortening velocity and myosin isoforms, 403–404
in fast and slow muscles, 401
heterogeneity of shortening velocity in fast fibers, 401–403
isometric tension and maximum power output, 404
force-velocity and other sarcomeric protein isoforms, 404–405
malignant hyperthermia defect, 539
malignant hyperthermia-susceptible
actions of volatile anesthetics, 573–579. *See also* Halothane
metabolic changes, 539–540
ultrastructure, 540
myofibrillar proteins. *See* Myofibrillar protein isoforms
myoplasmic calcium in, 542–544
conclusions, 544
determination using fura 2, 543
determination via calcium microelectrodes, 542–543
parathyroid hormone-related protein in, 164
resting tension and length-tension relations, 407–408
ryanodine receptor distribution, 1033–1037
cardiac muscle, 1036–1037
skeletal muscle, 1033–1036
smooth muscle, 1037
sarcomere structure and protein components, 372–382
smooth muscle. *See* Smooth muscle
Muscle biopsy, contracture testing, malignant hyperthermia susceptibility, 540
Muscle spindles, myofibrillar protein isoforms, 384–385
Mushroom body neurons
in *Drosophila* learning, 309–310
in *Drosophila* learning mutants, 310–312
physiological properties, 310–311
response properties and oscillations in, 311–312
Myelin, axon regeneration in spinal cord injury, 333–334, 339–340
Myocardial ischemia, cardiovascular control interactions in, 222–223
Myocardium, potassium channels, 49–62. *See also* Cardiac potassium channels
Myoepithelial cells, breast, markers, 73–77
Myofibrillar protein isoforms, 371–410
ATP hydrolysis and chemomechanical transduction, 395–400
ATPase kinetics and myosin isoforms, 398–400
myosin ATPase activity, 395–398
calcium sensitivity and regulatory proteins, 405–407
pCa-tension relationship of fast and slow fibers, 405–406
role of troponin and tropomyosin isoforms, 406–407
developmental patterns, 393–394
fatigue resistance, 409–410
fiber type-specific expression, 382–385
coexistence of multiple isoforms in same muscle fiber, 385
eye and ear muscles, 384
isoform profiles and fast and slow muscle fibers, 383–384
isoform profiles in particular muscle types, 384–385
laryngeal muscles, 384
mandibular muscles, 384
muscle spindles, 384–385
force-velocity and myosin isoforms, 400–405
correlations between shortening velocity and myosin isoforms, 403–404
force-velocity and body size, 405
force-velocity and isoforms of other sarcomeric proteins, 404–405
force-velocity relations in fast and slow muscles, 401
heterogeneity of shortening velocity in fast fibers, 401–403
myosin isoforms, isometric tension, and maximum power output, 404
functional roles, 395–410
ATP hydrolysis and chemomechanical transduction, 395–400
calcium sensitivity and regulatory proteins, 405–407
force-velocity and myosin isoforms, 400–405
resistance to fatigue, 409–410
resting tension and length-tension relations, 407–408
genes and generation of isoform diversity, 385–390
chromosomal localization, 386
gene structure and splicing processes, 385–386
molecular mechanisms of fiber type-specific gene regulation, 388–390
multigene families, 385–388
mutations and human disease, 386–388
transcriptional and posttranscriptional regulation, 390
patterns of isoform expression during muscle development, 390–395
developmental patterns, 393–394

diversity of muscle cell precursors and fiber types in embryonic muscle, 390–392
embryonic origin of myogenic cells, 391
factors affecting, 394–395
formation of primary and secondary muscle fibers and emergence of fiber types, 391
heterogeneity of myogenic precursors in tissue culture, 391–392
isoform switching during postnatal development, aging, and muscle regeneration, 392–393
postnatal diversification of fiber types and age-related isoform transitions, 392–393
satellite cells and isoform expression in regenerating muscle, 393
resting tension and length-tension relations, 407–408
sarcomere structure and protein components, 373–382. *See also* Sarcomere(s)
Myofibroblast(s), in breast cancer, 100–101
Myomesin, in sarcomeric muscle, 379–380
Myosin
ATPase activity, 395–398
ATPase kinetics and myosin isoforms, 398–400
breast myoepithelial cell expression, 75–76
force-velocity and myosin isoforms, 400–405
correlations between shortening velocity and myosin isoforms, 403–404
in fast and slow muscles, 401
heterogeneity of shortening velocity in fast fibers, 401–403
isometric tension and maximum power output, 404
proteins binding, 379–380
in sarcomeric muscles, 376–379
myosin essential light chains, 378
myosin heavy chains, 377–378
myosin regulatory light chains, 378–379
in smooth muscle contraction. *See* Smooth muscle contraction, myosin regulation
Myristoylated alanine-rich C-kinase substrate, in smooth muscle contraction, 985

N

NAD(P)H oxidase, in oxygen sensing, 861–862
Natriuresis, renal medullary circulation and, 505
Nebulin, in sarcomeric muscle, 381–382
Nemaline myopathy, 388
Nerve fibers, taste buds, 724
***N*-ethylmaleimide-sensitive factor (NSF),** in synaptic vesicle docking and fusion, 15
Neurexin(s), in synaptic vesicle docking and fusion, 15
Neuromuscular junction, *Drosophila* learning mutants, facilitation and posttetanic potentiation at, 312
Neuron(s)
cytosolic proteins, in synaptic vesicle docking and fusion, 15–16
plasma membrane proteins, in synaptic vesicle docking and fusion, 13–15
in rhythmic movement. *See* Rhythmic motor pattern generation
Neuropeptide(s), *Drosophila* learning mutants affecting, 307
Neuropeptide Y gene, insulin regulation of expression, 1127–1128
Neurotransmitter(s)
colocalization, 692
graded release, 692
release, nerve terminal membrane tracking, 1–19. *See also* Synaptic vesicle(s)
synaptic vesicle loading, 5
transport proteins, 5
Neurotrophic factors
in lesioned spinal cord, 337–338
in normal/developing spinal cord, 337
Neutrophil(s), in spinal cord injury, 328
N fibers, salty taste reception, 745
NFκB
insulin regulation of gene expression, 1134
molecular adaptation to hypoxia, 865
Nitric oxide. *See also* Endothelial factors
arterial baroreceptor interaction, short-term blood pressure control, 206–207
cellular actions, 435
in central control of cardiovascular system, 207–209
formation, 434–435
in peripheral neurotransmission, 210
renal vascular responses, 435–439
agonist-mediated nitric oxide release, 435
effect of nitric oxide substrate and donors, 436–437
inhibition of nitric oxide synthesis, 435–436
medullary circulation, 501–502
role in renal autoregulation, 438–439
sympathetic neurotransmitter release and, 209–210
Nitric oxide synthase
inhibition, renal microcirculatory responses, 437–438
regulation, growth hormone and, 1099
Nitrogen fixation, in symbiotic diazotrophs, 846–848
fixJ/fixL regulation, 847–848
pathways, 846–847
NSF (*N*-ethylmaleimide-sensitive factor), in synaptic vesicle docking and fusion, 15
Nuclear factor κB. *See* NFκB
Nuclear magnetic resonance spectroscopy. *See* Magnetic resonance spectroscopy
Nuclear protein transport, 651–675
cellular nuclear protein import apparatus, 660–666
cellular components, 660–666
factors mediating docking at nuclear pore complex, 661–662
factors mediating translocation through nuclear pore complex, 662–663
molecular chaperones, 663
nuclear localization signal binding proteins, 660–661
other components, 663
systems to measure nuclear protein import, 660
nuclear localization signals, 654–656
developmentally regulated, 670
factors affecting function, 658–659

alternative splicing, 659
piggyback and cell type-specific effects, 658–659
protein context and competing signals, 658
masking, 668–669
multiple signals/bitartite nuclear localization signals, 656–657
phosphorylation-regulated, 670–673
"CcN motif," 671–673
definition, 670–671
unidirectionality of nuclear localization signal-dependent nuclear protein transport, 673–674
nuclear pore complex, 652–654
components, 653–654
as molecular sieve, 652
structure, 652–653
nuclear protein export, 673–675
protein export from nucleus and nuclear export signals, 674
shuttling proteins, 674–675
unidirectionality of nuclear localization signal-dependent nuclear protein transport, 673–674
regulated (conditional) nuclear localization, 666–673
cytoplasmic retention, 666–667
cytoplasmic retention factors of Rel/Dorsal family, 667–668
developmentally regulated nuclear localization signals, 670
nuclear localization signal masking, 668–669
intra- and intermolecular masking, 668
phosphorylation and, 668–669
phosphorylation enhancing nuclear localization signal-dependent nuclear transport, 669–670
phosphorylation-regulated nuclear localization signals, 670–673
"CcN motif," 671–673
definition, 670–671
signals for nuclear targeting, 654–660
nuclear localization signals, 654–656
signals for localization to subnuclear compartments, 659–660
small nuclear ribonucleoprotein particles, 657
subnuclear compartment localization signals, 659–660
nucleolar localization signals, 659
signals for targeting to other subnuclear compartments, 659–660
summary and future prospects, 675

O

Olfactory classical conditioning, *Drosophila*, 313
Operant olfactory avoidance conditioning, *Drosophila*, 313
Osmotic stress, energy metabolism and, 810–812
Osteoblast differentiation, 593–617
bone-specific osteocalcin gene at onset of ECM mineralization in postproliferative osteoblasts, 605–612. *See also* Osteocalcin gene
contributions of promoter elements to steroid hormone and growth factor responsiveness, 610–612
nuclear structure and, 614–617
organization of osteocalcin gene, 605–606
promoter elements, 607–608
sequences mediating basal expression, 608–609
sequences mediating tissue-specific regulation of octeocalcin gene, 609–610
cell cycle-regulated histone genes in proliferating osteoblasts, 600–605
abrogation of growth control in transformed/tumor cells, 604
coordinate transcriptional control of histone and other S phase-related genes, 604–605
histone gene expression control, 600–601
posttranscriptional control, 601
transcriptional control, 601
nuclear structure and, 613–614
protein-DNA and protein-protein interactions at histone gene promotor element, 603–604
regulation of histone gene transcription, 602–603
chromatin structure and mucleosome organization
histone gene transcription and, 613–614
osteocalcin gene transcription and, 614–616
developmental expression of genes supported by an integrated cascade of signaling mechanisms mediating transcriptional control, 595–598
developmental transition-restriction points mediate proliferation-differentiation interrelationships during, 597–598
extracellular matrix-mediated control, 598
nuclear architecture and, 612–617
cell cycle stage-specific expression of histone genes in proliferating osteoblasts, 613–614
nuclear matrix
histone gene transcription and, 614
osteocalcin gene transcription and, 616–617
osteoblast developmental sequence, 594–600
gene expression, 595–596
model systems supporting progressive development of osteoblast phenotype, 594–595
proliferation supports unique requirements during each developmental stage, 596–597
protein-DNA and protein-protein interactions at histone gene promotor element during cell cycle and at onset of differentiation, 603–604
cell cycle control, 603
proliferation-differentiation interrelationships, 603–604
transcription factor phosphorylation, 604
steroid hormone and physiological mediators, 598–600
developmental stage-specific responsiveness, 598
dexamethasone and osteoblast phenotype development, 599
responsiveness, contributions of osteocalcin gene promoter elements, 610–612
synergistic, antagonistic, and cooperative transcriptional regulatory mechanisms, 599–600
transforming growth factor-β and osteoblast phenotype development, 599
windows of competency for physiological responsiveness and gating of osteoblast activity, 598–599

summary and prospects, 617
synergistic, antagonistic, and cooperative transcriptional regulatory mechanisms, 599–600
transcriptional control
bone-specific osteocalcin gene at onset of ECM mineralization in postproliferative osteoblasts, 605–612
cell cycle-regulated histone genes in proliferating osteoblasts, 600–605
contributions of nuclear architecture, 612–617
Osteocalcin gene
glucocorticoid responsive element, contributions to steroid hormone and growth factor responsiveness, 610–611
organization, 605–606
in postproliferative osteoblasts, transcriptional control, 605–612
promoter elements, 607–608
contributions to steroid hormone and growth factor responsiveness, 610–612
sequences mediating basal expression, 608–609
AP-1 sites and the E box, 609
homeodomain and runt homology protein binding sites, 609
silencer motif, 608–609
sequences mediating tissue-specific regulation, 609–610
transforming growth factor-β responsive element, contributions to steroid hormone and growth factor responsiveness, 612
vitamin D responsive element, contributions to steroid hormone and growth factor responsiveness, 611–612
Osteopetrotic *op/op* mouse. *See* Macrophage system
Ovary, parathyroid hormone-related protein in, 162
Oviduct, parathyroid hormone-related protein in, 142–143
Oxidative stress, in enteric bacteria, 845–846
Oxygen
effects in yeast, 850–858
effects in yeasts. *See also* Yeast, oxygen effects
effects on bacteria, 841–850
heme biosynthetic pathways, 849–850
hemoglobins, 848–849
nitrogen fixation in symbiotic diazotrophs, 846–848
oxidative stress in enteric bacteria, 845–846
respiratory systems in *Escherichia coli*, 841–845
effects on simple organisms, 840–841
Oxygen availability. *See* Anoxia; Hypercapnia; Hypoxia; Ischemia
Oxygen free radicals
in MHS pig muscle, 565
in spinal cord injury, 323
Oxygen sensing
in bacteria, 841–850. *See also* Oxygen, effects on bacteria
heme protein as sensor, 859–860
carotid body studies, 860
erythropoietin studies, 859–860
mitrochondria in, 862–863
multicellular organisms, 858–863
NAD(P)H oxidase in, 861–862
spectral analyses, 861
tissue localization, 861–862
peroxide production, 860–861
summary, 863
unicellular organisms, 840–858
in yeasts, 850–858. *See also* Yeast, oxygen effects

P

Pancreas, islets, parathyroid hormone-related protein in, 159–160
Parasitism, energy metabolism, nuclear magnetic resonance spectroscopy, 821–822
Parathyroid gland, parathyroid hormone-related protein in, 158–159
Parathyroid hormone-related protein, 127–164
conclusions, 164
gene, 129
history, 128–129
initial translation products (protein isoforms), 129
isoforms, 129
nomenclature, 129
paracrine/autocrine/intracrine vs. endocrine effects, 133
physiological functions, 133–164
in adrenal gland, 160–161
in amnion, 153
in central nervous system, 151
in chorion, 153
in choroid plexus, 164
in embryology, 133–136
in endocrine system, 158–162
in gastrointestinal tract, 143–144
in heart and coronary circulation, 146–148
in immune system, 163
in kidney, 149–151
in liver and biliary tree, 151
in lung, 148–149
in mammary gland, 138–140
in miscellaneous tissues, 163–164
in ovary, 162
in oviduct, 142–143
in pancreatic islets, 159–160
in parathyroid gland, 158–159
in pituitary gland, 161
in placenta, 153–154
potential, 154–155
in prostate gland, 162–163
in skeletal muscle, 164
in skeleton, 155–158
in skin, 136–138
in smooth muscle, 141–146
in testis, 162
in thyroid gland, 161
in umbilical cord and cord blood, 155
in urinary bladder, 143
in uterus, 141–142
in vascular system, 144–146
posttranslational processing, 130–132
receptors and signal transduction pathways, 132

secretion, 132
thematic roles (function), 132–133
PC-1 gene, expression in non-insulin-dependent diabetes mellitus, 1142–1143
Pericyte(s), breast, 86–89
Peripheral nerve(s), grafts, as bridges in adult spinal cord lesions, 334–335
pH
changes, energy metabolism and, 810–812
ryanodine receptor activity, 556
Phosphagens, in energy metabolism, nuclear magnetic resonance spectroscopy, 822–824
Phosphatidylinositol 3′-kinase
in growth hormone signaling, 1096–1097
in insulin-regulated gene transcription, 1134–1135
Phosphatidylinositol metabolism, in MHS pig muscle, 564–565
Phosphatidylinositol-4-phosphate 5-kinase (PIP5K), in synaptic vesicle docking and fusion, 16
Phosphatidylinositol transfer protein (PITP), in synaptic vesicle docking and fusion, 16
Phosphodiesterase, in bitter taste, 737
Phosphodiesters, in energy metabolism, nuclear magnetic resonance spectroscopy, 825–827
Phospho*enol*pyruvate carboxykinase gene
expression in non-insulin-dependent diabetes mellitus, 1140–1141
insulin regulation of expression, 1121–1124
Phospholipase C, in bitter taste, 736–737
Phospholipid(s), hydrolysis, in spinal cord injury, 323
Phosphorylation
gastrin processing, 780–781
growth hormone-dependent tyrosyl phosphorylation of growth hormone receptor and JAK2, 1095
20-kDa myosin light chains, in smooth muscle contraction, 978–979
modulation of sodium channels in heart and brain, 910–911
molecular adaptation to hypoxia, 863–864
nuclear localization signal-dependent nuclear protein transport, 669–670
nuclear localization signal masking, 668–669
protein transport to nucleus, 651–675. *See also* Nuclear protein transport
ryanodine receptor activation state and, 1042
Physical stress, cardiovascular control interactions in, 216–218
Pituitary gland, parathyroid hormone-related protein in, 161
Placenta, parathyroid hormone-related protein in, 153–154
potential physiological roles, 154–155
Platelet-derived growth factor, in breast cancer, 104
Podocyte(s), tight junctions, 251–252
Polarity, kidney epithelial cells, 245–247. *See also* Epithelial cells; Kidney epithelium
Polycystic kidney disease, protein trafficking and epithelial cell polarity in, 287
Porins, 1073–1087
architecture, 1076–1081
central structural motif: β-cylinder, 1076–1080
substructure, 1080–1081
bacterial outer membrane, 1074–1075
concluding remarks, 1086–1087
β-cylinder, 1076–1080
functional mechanism, 1081–1086
porin channel sterics and electrostatics, 1083–1085
voltage-dependent gating, 1086
water-coordinated transport model, 1085–1086
structural studies, 1075–1076
substructure, 1080–1081
contriction region, 1081
external mouth and vestibule, 1080–1081
internal vestibule and mouth, 1081
Potassium, in spinal cord injury, 323
Potassium channels
blockage, in bitter taste, 736
myocardium. *See* Cardiac potassium channels
Potassium chloride, taste, 746–747
Pregnancy, cardiovascular control interactions in, 220
Principal cells, renal collecting duct, 281–283
Proboscis extension reflex (*Drosophila*)
habituation of, 314
Pavlovian conditioning, 314
sensitization of, 314
Prolactin gene, insulin regulation of expression, 1114–1116
Prolyl isomerase activity, immunophilins, 636
Propofol, actions in MHS muscle, 578
Prostacyclin. *See* Endothelial factors
Prostaglandin(s), renal vascular actions, medullary circulation, 502
Prostate gland, parathyroid hormone-related protein in, 162–163
Protein(s)
cytoskeletal, smooth muscle contraction, 992
immunophilins, 631–644
myofibrillar, 371–410
p115, in synaptic vesicle docking and fusion, 16
p145, in synaptic vesicle docking and fusion, 16
parathyroid hormone-related protein, 127–164
ryanodine receptor-related, 1030
synaptic vesicle, 2–3
transport, 267–277
G proteins in, 275–277
to nucleus. *See* Nuclear protein transport
protein sorting and transport pathways, 267–268
renal. *See* Kidney epithelium, protein trafficking
sorting signals on proteins, 268–273
transport vesicles, 273–277
vesicle budding, 274–275
vesicle fusion, 275
Protein kinase
calcium/calmodulin-dependent, in *Drosophila* learning, 308
mitogen-activated. *See* Mitogen-activated protein kinase
Protein kinase C
Drosophila learning mutants affecting, 307–308
in growth hormone signaling, 1097–1098
in insulin-regulated gene transcription, 1135–1136
in smooth muscle contraction, 900–985. *See also* Smooth muscle contraction

Protein toxins, 949–960
directions for future research and perspectives, 960
endocytosis, 951–953
endosome sorting in, 953
mechanisms, 951–953
intracellular processing of Shiga toxin, 958
structure and physical properties, 950–951
targeted delivery of (immunotoxins), 959–960
toxin transport
retrograde transport to endoplasmic reticulum, 956–958
to *trans*-Golgi network and importance for intoxication, 953–955
Proteoglycans, neurite growth inhibition, 341
Proton pump(s), in intercalated cells of collecting duct, 283–287
hydrogen ATPase-coated acidic vesicles in, 283
opposite polarity in A and B intercalated cells, 283–287
Purine compounds. *See also* Adenosine; Adenosine triphosphate
metabolism, 461–472
Purinoceptors
P_2 receptor and renin secretion, 479
renal vascular regulation, 469–470
Pyloric system, rhythmic motor pattern generation, 693–695

R

Rab3A, in synaptic vesicle docking and fusion, 12–13
Rabphilin 3A, in synaptic vesicle docking and fusion, 13
Rad, expression in non-insulin-dependent diabetes mellitus, 1143
Remyelination, in spinal cord injury, physiological relevance, 329
Renal microcirculation, 425–506
activation and signaling mechanisms in renal arteriolar segments and mechanosensitive responses, 428–433
angiotensin II and, 467–469
differential activation mechanisms in afferent and efferent arterioles, 430–432
mechanosensitive responses of renal vasculature, 432–433
membrane activation and signal transduction mechanisms, 428–430
angiotensin II actions on microvasculature, 459–465
effects of ANG II on renal microcirculation, 461
effects of exogenous ANG II on renal and single-nephron hemodynamics, 459–461
indirect effects of ANG II receptor blockade on renal hemodynamics, 464
interactions between ANG II and sympathetic nervous system in regulation of renal hemodynamics, 465
kinin-mediated component to the responses to ACE inhibitors, 462–463
response to ACE inhibitors and ANG II receptor blockers, 461–462
role of intrarenally formed ANG II, 464–465
segmental microcirculatory responses to ANG II blockade, 463–464
angiotensin II and
differential activation and signal transduction mechanisms, 467–469
interactions between renal vascular and tubular effects, 465–467
synergistic actions of ANG II on proximal reabsorption rate and tubuloglomerular feedback responsiveness, 467
tubuloglomerular feedback responsiveness and, 465–467
angiotensin II receptors in, 458–459
localization, 458
subtypes and their intrarenal distribution, 458–459
arachidonic acid metabolites and, 485–497. *See also* Arachidonic acid metabolites
angiotensin II interactions, 492–493
cyclooxygenase metabolites, 487–490
lipoxygenase-derived substances, 490–491
metabolite formation and relative prominence in kidney, 485–487
modulators of renal vascular actions by other paracrine systems, 492–495
autoregulation
arachidonic acid metabolites in, 495
localization of resistance changes during, 451–452
mediation, tubuloglomerular feedback mechanism in, 451–453
medullary circulation, 503–505
myogenic vs. tubuloglomerular mechanisms, 452–453
nitric oxide in, 438–439
possible roles of purine agents, 483–485
regional renal blood flow responses, 453
search for mediator of, 453
theories on, 451
tubuloglomerular feedback mechanism in, 451–453
differential activation mechanisms in afferent and efferent arterioles, 430–432
activation mechanisms in mesangial cells, 432
angiotensin II and, 468–469
direct evidence for, 430–432
early support for, 430
effects of cyclooxygenase metabolites, 487–490
renal metabolism, receptors, and signal transduction, 487–489
renal vascular actions, 489–490
effects of cytochrome P-450 metabolites, 491–492
effects of lipoxygenase-derived substances, 490–491
renal metabolism, receptors, and signal transduction, 490
renal vascular actions, 490–491
endothelial-derived paracrine influences, 433–443
endothelin and renal hemodynamics, 440–443
nitric oxide interactions with other vasoactive factors, 439–440
nitric oxide-mediated responses, 435–439
vasoactive factors, 433–435
cellular actions of nitric oxide, 435
formation of nitric oxide, 434–435
endothelin and renal hemodynamics, 440–443
cellular mechanisms of endothelin action, 442–443
endothelin and endothelin receptors, 440–441
endothelin effects on renal hemodynamics, 441
endothelin effects on renal microcirculation, 441–442
endothelin interactions with other vasoactive factors, 442
epithelial-derived vasoactive factors, 443–444, 453–456
formation of, 443–444

kallikrein-kinin system, 453–456
kallikrein-kinin system in, 453–456
components of intrarenal kallikrein-kinin system, 453–454
mechanisms of bradykinin's vasodilator action, 455
renal vascular responses to bradykinin receptor blockers, 455–456
renal vascular response to bradykinin infusions, 454–455
mechanosensitive responses of renal vasculature, 432–433
cellular mechanisms mediating, 432–433
"myogenic" response, 432
medullary circulation, 497–505
angiotensin II and, 500–501
arginine vasopressin and, 498–500
autoregulation, 503–505
differential regulation by vasoactive factors, 498–502
hormonal interactions regulating, 502–503
involvent of changes in blood flow in pressure natriuresis and blood pressure control, 505
kinins and, 502–503
nitric oxide and, 501–502
prostaglandins and, 502
response to changes in perfusion pressure, 503–505
structural features, 497–498
study methodologies, 498
membrane activation and signal transduction mechanisms, 428–430
activation of cytosolic calcium and vascular smooth muscle cell contraction, 428–430
cAMP- and cGMP-dependent mechanisms, 430
nitric oxide interactions with other vasoactive factors, 439–440
renin-angiotensin system, 439–440
nitric oxide-mediated responses, 435–439
agonist-mediated nitric oxide release, 435
autoregulation, 438–439
effect of nitric oxide substrate and donors, 436–437
inhibition of nitric oxide synthesis, 435–436
renal microcirculatory responses to nitric oxide synthase inhibition, 437–438
paracrine regulation
arachidonic acid metabolites, 485–497
conclusions and future perspectives, 505–506
endothelial-derived paracrine influences, 433–443
epithelial-derived vasoactive factors and tubuloglomerular feedback mechanism, 443–456
purine paracrine agents, 469–485
renin-angiotensin system, 456–469
purine paracrine regulation, 469–485. *See also* Adenosine; Adenosine 5′-triphosphate
adenosine actions on renal vasculature, 473–476
adenosine and regulation of renin secretion, 478–479
adenosine interactions with other paracrine systems, 476–478
adenosine 5′-triphosphate actions on renal vasculature, 479–483
formation and release of adenosine and ATP, 470–473
possible roles of purine agents in tubuloglomerular feedback mechanism and in autoregulation, 483–485
purinoceptors and vasoactive purine agonists, 469–470
adenosine or P_1 receptors, 469–470
renin-angiotensin system, 456–469
angiotensin II actions on renal microvasculature, 459–465
angiotensin II receptors in, 458–459
components, 456–457
interactions between renal vascular and tubular effects of ANG II, 465–467
intracellular formation of angiotensins I and II, 457–458
intrarenally formed angiotensin II, 457
tubuloglomerular feedback mechanism, 444–453
in autoregulatory response, 451–453
basic characteristics, 444–446
interstitial electrolytes as signaling mechanisms, 449
luminal activating mechanism, 446–447
macula densa signaling mechanisms, 447–448
mediation of macula densa signals to vascular smooth muscle cells, 448–449
modulation of sensitivity, 450–451
Renin-angiotensin system. *See also* Angiotensin I; Angiotensin II
nitric oxide interactions, 439–440
renin secretion
adenosine and, 478–479
P_2 receptor activation and, 479
Reticulocyte(s), transferrin-independent iron transport in, 38–39
Rhythmic motor pattern generation, 687–710
behaviors controlled by pattern generators, 688
circuit building blocks, 688–693
intrinsic cellular properties, 689–692
modulation of intrinsic membrane properties, 690–692
neuronal oscillators and plateau neurons, 689–690
voltage dependency, 690
network modules, small networks, 693
pattern-generating neurons, 688–689
synaptic connections, 692–693
colocalized neurotransmitters, 692
electrical coupling, 692–693
graded release of neurotransmitter, 692
time course of synaptic currents, 692
circuit switching, 705–708
stomatogastric nervous system, 706–708
Tritonia swim and reflex withdrawal, 706
Clione and *Xenopus* swimming, 695–697
command neurons, reevaluating the concept, 708–709
conclusions, 708–710
elemental pattern generators
Clione and *Xenopus* swimming, 695–697
gastric rhythm, 699–701
half-center oscillations, general theoretical considerations, 698–699
intrinsic membrane properties and reciprocal inhibition, 693–701
leech heartbeat, 697–698
pyloric system, 693–695
gastric rhythm, 699–701
half-center oscillations, general theoretical considerations, 698–699
intersegmental coordination, 701–705

lamprey, 702–704
leech, 704–705
other preparations, 705
leech heartbeat, 697–698
organizational rules, 709–710
physiological and computational approaches, 693–708
circuit switching, 705–708
elemental pattern generators, 693–701
intersegmental coordination, 701–705
pyloric system, 693–695
Ribonucleic acid, messenger. *See* mRNA
Ricin. *See* Protein toxins
Ryanodine receptor, 1027–1061. *See also* Malignant hyperthermia, malignant hyperthermia-susceptible pigs
activation
adaptation, 1041–1042
calmodulin and, 1043–1044
luminal calcium and, 1041
phosphorylation and, 1042
redox state and, 1044
sarcoplasmic reticulum calcium release, 1037–1041
voltage and, 1042–1043
calcium release systems
muscle cell functions of individual RyR isoforms, 1044–1057
experimental approaches, 1044–1045
muscle cell structure and organization, 1045–1046
two vs. one, 1044–1057
muscle cell functions of individual RyR isoforms, 1044–1057
cellular distributions, 1032–1037
cardiac muscle, 1036–1037
nonmuscle cells, 1032–1033
smooth muscle, 1037
vertebrate skeletal muscle, 1033–1036
concluding remarks, 1060–1061
defect, influence of fiber type in, 558–559
in embryonic skeletal muscle development, 1057–1060
developmental stage-specific expression of avian α- and β-RyR, 1057–1059
isoform vs. activation mechanism paradox, 1059
sarcoplasmic reticulum calcium release and normal development, 1059–1060
sequential expression of cardiac and skeletal muscle-specific protein isoforms, 1059
sequential use of cardiac and skeletal muscle-like mechanisms to activate sarcoplasmic reticulum calcium release, 1059
FK506 binding proteins and, 637–643
gene expression, in different tissues, 579
invertebrate ryanodine receptors, 1029
isoforms, in embryonic skeletal muscle development, 1057–1060
metabolites that interact with, 556–557
molecular diversity, 1028–1030
muscle cell functions of individual RyR isoforms, 1044–1057
distribution of RyR isoforms, 1046
experimental approaches, 1044–1045
muscle cell structure and organization, 1045–1046
junctional organization, 1045–1046
specialized structural role for one ryanodine receptor, 1046
two RyR calcium release system specialization for contractile function, 1046–1057
properties in heterozygous pigs, 557–558
Ca^{2+} release and [^{3}H]ryanodine binding of sarcoplasmic reticulum vesicles, 557–558
contractile activity of muscle bundles, 557
responses of whole animals to malignant hyperthermia triggers, 557
ryanodine receptor single-channel activity, 558
properties in sarcoplasmic reticulum vesicles and lipid bilayers, caffeine action, 559–560
related proteins, 1030
sarcoplasmic reticulum calcium release. *See also* Sarcoplasmic reticulum, calcium release
single-channel activity in MHS muscle
in humans, 569
in pigs, 550–551
volatile anesthetics and, 575–576
species and tissue distributions, 1031–1032
vertebrate ryanodine receptor isoforms and splice variants, 1028–1029

S

Salt deprivation, salty taste reception, 748
Salty taste. *See* Taste reception
Sarcomere(s)
structure and protein components, 373–382
thick filaments, 376–380
thin filaments, 373–376
titin and nebulin filaments, 380–382
Z disks, 382
thick filaments, 376–380
myosin, 376–379
myosin-binding proteins, 379–380
C protein, 379
H protein, 379
M protein, 379–380
myomesin, 379–380
myosin isoforms
myosin essential light chains, 378
myosin heavy chains, 377–378
myosin regulatory light chains, 378–379
thin filaments, 373–376
actin isoforms, 373
tropomodulin isoforms, 376
tropomyosin isoforms, 373–374
troponin isoforms, 374–376
troponin C, 374–375
troponin I, 375
troponin T, 375–376
titin and nebulin filaments, 380–381

nebulin, 381–382
titin (connectin) isoforms, 380
Z disks, 382
α-actinin isoforms, 382
CapZ and other Z-disk components, 382
Sarcoplasmic reticulum
Ca^{2+}-ATPase pump, in smooth muscle contraction, 971
calcium binding proteins, in smooth muscle contraction, 971
calcium regulation, in smooth muscle contraction, 970–971
calcium release
activation in skeletal muscle, 1037–1040
calcium-induced, 1039–1040
directly coupled calcium release, 1037–1039
inositol 1,4,5-trisphosphate-induced, 1040
deactivation and inactivation in skeletal muscle, 1040–1041
calcium-induced inactivation, 1041
voltage-induced deactivation, 1041
in malignant hyperthermia-susceptible humans, 568–570
in malignant hyperthermia-susceptible muscle, volatile anesthetics and, 574–576
in malignant hyperthermia-susceptible pigs, 546–553
normal muscle development, 1059–1060
sequential use of cardiac and skeletal muscle-like mechanisms to activate, 1059
two-ryanodine receptor calcium release system, 1046–1047, 1052–1056
calcium transport, in MHS muscle, volatile anesthetics and, 573–574
calcium uptake and storage
in malignant hyperthermia-susceptible humans, 567–568
in malignant hyperthermia-susceptible pigs, 545–546
ultrastructure, 972
Scar formation, in spinal cord injury, physiological relevance, 329
Schwann cell(s), implants, in spinal cord injury, 335–336
Sepsis, in *op/op* mouse, role of macrophages, 940–941
Serotonin, entrochromaffin cells, 788
Shiga toxin. *See* Protein toxins
Sialomucin, breast epithelial cell expression, 72
Signal transduction. *See also specific physiological processes*
growth hormone, 1089–1101
in hypoxia, 863–867
insulin-like growth factor receptor I, 1007–1008
protein kinase C activation and smooth muscle contraction, 983–985
in taste reception. *See* Taste reception
Skeletal muscle. *See* Muscle
Skeletal system, parathyroid hormone-related protein in, 155–158
Skin
development, differentiation, and cell death, insulin-like growth factor action, 1017
parathyroid hormone-related protein in, 136–138
Smooth muscle
contractility. *See* Smooth muscle contraction
parathyroid hormone-related protein in, 141–146
ryanodine receptor distribution, 1037
vascular. *See* Vascular smooth muscle cells
Smooth muscle contraction, 967–992
conclusions, 992
intracellular free Ca^{2+} regulation, 968–974
interactions between sarcolemmal channels, pumps, exchangers, and calcium stores, 972–974
capacitation calcium entry model, 973–974
functional integration, 973
superficial buffer barrier model, 973
ultrastructure, 972–973
molecular elements, 969–972
myoplasmic buffering molecules, 972
sarcolemmal channels, 969–970
sarcolemmal ion exchangers and pumps, 970
sarcoplasmic reticulum Ca^{2+}-ATPase pump, 971
sarcoplasmic reticulum Ca^{2+} binding proteins, 971
sarcoplasmic reticulum channels, 970–971
20-kDa myosin light chains, 985
phosphorylation of, 978–979
myosin regulation, 974–980
latch hypothesis, 979–980
myosin light chain kinase, 976–978
myosin light chain phosphatase, 979
phosphorylation of 20-kDa myosin light chains, 978–979
smooth muscle myosin, 974–976
protein kinase C in, 980–985
effect of PKC inhibitors on contraction, 982
evidence supporting, 981–983
isoforms, 980–981
phorbol ester-induced contraction with/without calcium, 981–982
signaling pathways, 983–985
caldesmon, 984
calponin, 984–985
20-kDa myosin light chain, 985
mitogen-activated protein kinase, 983–984
myristoylated alanine-rich C-kinase substrate, 985
small GTP-binding proteins, 984
sustained diacylglycerol generation during agonist-induced contraction, 981
temporal patterns of PKC activation and correlation with contraction, 982–983
thin filament regulation, 985–992
caldesmon in, 986–989
calponin in, 989–992
cytoskeletal proteins, 992
evidence for, 985–986
SNAPS (soluble NSF attachment proteins), synaptic vesicle docking and fusion, 15–16
SNAP-25 (synaptosomal-associated protein of 25 kDa), in synaptic vesicle docking and fusion, 14
Sodium/calcium exchanger, smooth muscle, 970
Sodium channel(s)
amiloride-blockable, in salt taste, 739–740
cardiac and nerve channels, 887–920
activation gate, mutagenesis data, 918
comparison of kinetics in wild-type channels, 912–917

current-voltage relationship, 912–913
differences in activation revealed by gating currents, 915
time course, 912
voltage dependence of inactivation, 916–917
voltage-dependent channel availability, 914–915
cytoplasmic regions, 896–898
domain connectors, 898
NH_2- and COOH-terminals, 897–898
segment linkers, 896–898
S2-S3 linkers, 897
S4-S5 linkers, 897
divalent ions and, 907–909
direct block of channel, 909
surface charge, 908–909
extracellular segments, 894–896
P segment, 896
S5-P and P-S6 segments, 894
S1-S2 and S3-S4 linkers, 894
homology, 890
inactivation, mutagenesis data, 919–920
involvement in disease, 920
isoform differences in kinetics, 911–920
framework for comparison, 911–912
insights into gating from mutagenesis, 917–920
wild-type channels, 912–917
modulation by phosphorylation, 910–911
permeation path, 899–910
chemical modification by carboxyl-reactive agents, 901
comparison with calcium channel, 905–906
divalent ions and, 907–909
guanidinium toxins as channel probes, 900–901
inner vestible, 906
Lipkind-Fozzard vestibule/selectivity filter model, 903–905
location of sodium channel selectivity filter, 900
selectivity and sodium channel pore, 899–906
single-channel conductance, 906–907
summary, 909–910
toxin affinity differences between nerve and heart, 902–903
toxin-binding site/channel vestibule, 901–902
protein structure, 888–899
chemistry, 888–889
cytoplasmic regions, 896–898
extracellular regions, 894–896
homology, 890
primary structure, 889
β-subunits, 898–899
tertiary structure, 890–891
topology, 889–890
transmembrane segments, 891–894
tertiary structure, 890–891
topology, 889–890
transmembrane segments, 891–894
comparison of S4 segments, 892
S1-S6, 892
voltage sensing, mutagenesis data, 917–918
involvement in disease, 920
Sodium-hydrogen antiporter, in proximal renal tubule, 278–279
Somatostatin
biological properties, 782
posttranslational processing. *See* Gastric endocrine cells
Somatostatin gene, 771–773
cDNA sequences, 771–772
cell-specific expression, 772
genomic organization, 772
physiological regulation of expression, 772–773
antral D cells, 772–773
corpus D cells, 773
Sour taste. *See* Taste reception
Spinal cord injury, 319–352
acute phase
histopathological evolution of lesion site, 324
pathophysiology, 322–323
axon regeneration, 329–337
age-dependent loss of regeneration of lesioned axons in spinal cord of higher vertebrates, 332
inhibitors of and barriers to, 339–344
neurite growth of transplanted embryonic neurons into adult spinal cord, 336–337
neurotrophic factors and, 338
peripheral nerve grafts as bridges in adult spinal cord lesions, 334–335
purified Schwann cell implants, 335–336
regeneration in rat/chick spinal cord deprived of myelin or in presence of MAb against myelin-associated neurite growth inhibitors, 333–334
regeneration of lesioned axons into grafts of peripheral nerves, Schwann cells, artificial bridges, or embryonic CNS tissue, 334–336
regeneration of spinal pathways in amphibians and fish, 332–333
responses of CNS neurons to axotomy, 329–332
transplants of embryonic CNS tissue, 336
clinical considerations, 347–352
clinical management strategies, 350–352
epidemiology, 347–348
experimental and clinical studies for neuroprotective treatment, 348–350
initial evaluation, 350–351
conclusions, 352
epidemiology, 347–348
excitotoxins in, 323
experimental animal models, 321–322
functional aspects of regeneration and reorganization of fiber connections, 344–347
functional improvements under experimental influences, 346–347
sparing of functions after partial lesions and autonmic functions of spinal cord, 344–345
sprouting and plastic changes, 345–346
histopathological evolution of lesion site, 323–327
acute phase, 324
late phase, 326–327

subacute phase, 324–326
human, 320–321
inflammatory response, 323
physiological relevance of cellular processes at lesion site, 327–329
inhibitors of and barriers to regeneration, 339–344
inhibition of myelin-associated neutrite regeneration, 339–340
lesion scar, 342–344
neurite growth inhibitory/repulsive molecules, 340–342
late phase, histopathological evolution of lesion site, 326–327
nature of injury, 320–322
neuronal responses to axotomy, 329–332
expression of growth-associated genes by axotomized spinal neurons, 330–331
sprouting of lesioned spinal cord axons, 331–332
survival vs. cell death, 330
neuroprotective treatment, experimental and clinical studies, 348–350
neurotrophic factors that stimulate neurite growth and regeneration in spinal cord, 337–338
partial, functional aspects, 344–345
pathophysiology of acute phase, 322–323
blood flow changes and ischemia, 322
edema, 322
excitotoxins, 323
inflammatory response, 323
metabolites, calcium, and potassium, 322–323
phospholipid hydrolysis and free radical formation, 323
physiological relevance of cellular processes at lesion site, 327–329
demyelination/remyelination, 329
glial scar formation, 329
posttraumatic inflammatory response, 327–329
rapid posttraumatic cell death, 327
scar formation, 342–344
subacute phase, histopathological evolution of lesion site, 324–326
substrates that stimulate neurite growth and regeneration in spinal cord, 338–339

Stat family proteins, activation, growth hormone and, 1099–1100

Steroid hormones, in osteoblast proliferation and differentiation, 598–600
nuclear structure and osteocalcin gene expression, 614–617

Stomach
endocrine system. *See* Gastric endocrine cells
rhythmic pattern generation, 699–701

Stomatogastric nervous system, rhythmic motor pattern generation, 706–708

Stress, cardiovascular control interactions in, 216–218

Sucrose reward learning, *Drosophila,* 313

Sulfation, gastrin processing, 780

Sweet taste. *See* Taste reception

Swimming, rhythmic motor pattern generation
Clione and *Xenopus* spp., 695–697
intersegmental coordination, 701–705
lamprey, 702–704
leech, 704–705
Tritonia, 706

Sympathetic nervous system
angiotensin II interactions, regulation of renal hemodynamics, 465
in malignant hyperthermia, 580

Synaptic transmission
rhythmic motor pattern generation, 692–693. *See also* Rhythmic motor pattern generation
synaptic vesicle biogenesis, docking, and fusion, 1–19

Synaptic vesicle(s), 1–19
biogenesis, 2–8
cytoskeletal association, 5–6
endocytosis and local recycling, 6–7
localization, 3–4
protein sorting, 4–5
protein synthesis, 2–3
protein turnover, 7–8
conclusion, 19
docking and fusion, 8–19
assembly of 7S complex, 17
assembly of 20S complex, 17
biophysical analysis, 8
candidate proteins, 8–16
coiled-coil domains of synaptic proteins, 18–19
cytosolic proteins, 15–16
additional proteins, 16
annexins, 16
Exo 1, 16
n-sec1, 15
NSF (*N*-ethylmaleimide-sensitive factor), 15
p115, 16
p145, 16
phosphatidylinositol-4-phosphate 5-kinase (PIP5K), 16
phosphatidylinositol transfer protein (PITP), 16
SNAPS (soluble NSF attachment proteins), 15–16
disassembly of 20S complex, 17–18
isoform specificity in complex formation, 18
membrane fusion, 18
model for, 16–19
plasma membrane proteins, 13–15
GAP-43, 14–15
neurexins, 15
SNAP25, 14
syntaxin, 13–14
synaptic vesicle membrane proteins, 10–13
cysteine string protein, 12
rab3A, 12–13
rabphilin 3A, 13
synaptophysin, 11
synaptotagmin, 11–12
vesicle-associated (VAMP), 10–11
endocytosis and local recycling, 6–7
candidate proteins, 7
kinetics, 6–7
location, 6
specialized endosomes, 7

localization, 3–4
neurotransmitter loading, 5
protein sorting, 4–5
protein synthesis, 2–3
protein turnover, 7–8
Synaptophysin, in synaptic vesicle docking and fusion, 11
Synaptosomal-associated protein of 25 kDa (SNAP-25), in synaptic vesicle docking and fusion, 14
Synaptotagmin, in synaptic vesicle docking and fusion, 11–12
Syntaxin, in synaptic vesicle docking and fusion, 13–14

T

Taste buds
basal stem cells, 724
cell types, 721–725
discoid, of frogs, 725
elongated cells, 721–723
Merkel-like cells, 725
nerve fibers, 724
surface marker molecules, 724
Taste reception, 719–754
bitter taste, 736–739
amphiphilic peptides in, 737–738
cellular response management, 738–739
cAMP as "no input" signal, 738–739
inositol 1,4,5-trisphosphate and Ca^{2+} release, 738
membrane potential, 738
conclusion, 739
gustducin and transducin in, 737
input events, 736–738
K^+ channel blockage in, 736
mediation by phosphodiesterase, 737
mediation by phospholipase C, 736–737
cell lineage and maintenance, 725–726
cell types, 721–725
basal stem cells, 724
conclusion, 725
discoid taste buds of frogs, 725
elongated cells, 721–723
Merkel-like cells, 725
nerve fibers, 724
surface marker molecules, 724
electric taste, 751–753
receptor cell polarity, 726–728
action potentials, 726–728
cell-to-cell coupling, 728
ion channels, 726
receptor cell specificity, 728–729
salty taste, 739–748
aldosterone and, 747–748
amiloride-blockable Na^+ channels, 739–740
amiloride-insensitive component, 745
antidiuretic hormone and, 748
cellular response management, 747
cloning and in situ hybridization, 743–744
Conclusion, 748
electrophysiology
in situ loose-patch recordings, 740
single-channel properties, 741
whole cell currents, 740–741
enhancement of salt taste, 745–746
hormonal effects and homeostasis, 747–748
immunohistochemistry, 741–743
input events, 739–744
cloning and in situ hybridization, 743–744
immunohistochemistry, 741–743
in situ loose-patch recordings, 740
single-channel properties, 741
whole cell currents, 740–741
modulation, 744–747
N fibers and H fibers, 745
para-taste receptor cell pathways and anion component of salt taste, 744–745
potassium chloride taste, 746–747
sodium deprivation and, 748
species differences, 746
sour taste, 750–751
cellular response management, 750
conclusion, 751
input events, 750
modulation, 750–751
summary and perspectives, 753–754
sweet taste, 729–734
amiloride-blockable, 730
cAMP in, 731
cellular response management, 731–734
changes in free cytosolic Ca^{2+}, 732–733
dual signaling, 733–734
membrane effects of cyclic nucleotides, 731–732
conclusion, 734
G proteins in, 730–731
inositol 1,4,5-trisphosphate in, 731
input events, 729–731
receptor, 729–730
taste categories, 720–721
umami, 734–736
cellular response management, 735–736
conclusion, 736
L-glutamate, 735
input events, 734–735
receptors, 735
sensing of amino acids, 734–735
water taste, 749–750
Tenascin, neurite growth inhibition, 341
Testis, parathyroid hormone-related protein in, 162
Thyroglobulin gene, insulin regulation of expression, 1118
Thyroid gland, parathyroid hormone-related protein in, 161
Thyroperoxidase gene, insulin regulation of expression, 1118–1119

Thyrotropin receptor gene, insulin regulation of expression, 1119
Thyrotropin-releasing hormone, 175
desensitization, 183–184
Thyrotropin-releasing hormone receptors, 175–187
activation, 183
binding pocket, three-dimensional structure, 178–181
conclusion, 187
desensitization, 183–184
endocytosis, 184–185
gene, 175–177
G protein coupling, 181–183
number, regulation, 185–187
regulation, 185–187
structure, 177–178
tissue distribution, 177
Tight junctions
in kidney tubules, 251–252
collecting duct, 251
distal convoluted tubule, 251
podocytes, 251–252
proximal tubule, 251
thick ascending limb of Henle, 251
thin limbs of Henle, 251
structure, 247–251
Titin, in sarcomeric muscle, 380
Transducin, in bitter taste, 737
Transferrin, iron assimilation in mammalian cells, 32–33
Transferrin receptor, iron assimilation in mammalian cells, 33
Transforming growth factor-β
in breast cancer, 103–104
osteoblast phenotype development, 599
osteocalcin gene, 612
Transforming growth factor-β receptor, FK506 binding protein interactions, 643
Trauma
in *op/op* mouse, role of macrophages, 941
spinal cord injury. *See* Spinal cord injury
***Tritonia* spp.,** swim and reflex withdrawal, 706
Tropomyosin
calcium sensitivity of myofibrillar apparatus, 406–407
in sarcomeric muscles, 373–374
Troponin(s)
calcium sensitivity of myofibrillar apparatus, 406–407
in sarcomeric muscles, 374–376
troponin C, 374–375
troponin I, 375
troponin T, 375–376
Tubuloglomerular feedback mechanism, 444–453
arachidonic acid metabolites in, 496–497
in autoregulatory response, 451–453
localization of resistance changes during autoregulatory responses, 451–452
myogenic vs. tubuloglomerular mechanisms, 452–453
regional renal blood flow responses, 453
theories on renal autoregulation, 451
basic characteristics, 444–446
interstitial electrolytes as signaling mechanisms, 449
luminal activating mechanism, 446–447
macula densa signaling mechanisms, 447–448
mediation of macula densa signals to vascular smooth muscle cells, 448–449
modulation of sensitivity, 450–451
possible roles of purine agents, 483–485
responsiveness, angiotension II and, 465–467
Tumorigenesis
insulin-like growth factor I receptor in, 1018
in *op/op* mouse, role of macrophages, 941
Tumor necrosis factor-α, in breast cancer, 105
Tumor necrosis factor-α gene, expression in non-insulin-dependent diabetes mellitus, 1142–1143
Tyrosine aminotransferase gene, insulin regulation of expression, 1125–1126
Tyrosine hydroxylase, hypoxic induction, 870–871
animal studies, 870
regulation of mRNA stability, 870–871
transcriptional regulation, 870
Tyrosine kinase
JAK2
growth hormone-dependent tyrosyl phosphorylation of, 1095
growth hormone signaling, 1093–1095
nuclear, in insulin-regulated gene transcription, 1136
Tyrosine-*O*-phosphate, in energy metabolism, 828

U

Umami. *See* Taste reception
Umbilical cord, parathyroid hormone-related protein in, 155
Urinary bladder, parathyroid hormone-related protein in, 143
Uterus, parathyroid hormone-related protein in, 141–142

V

Vascular endothelial growth factor, hypoxic induction, 871–872
mRNA expression, 871
regulation of mRNA stability, 872
transcriptional regulation, 871–872
Vascular permeability factor, in breast cancer, 104
Vascular smooth muscle cells
aortic, cultivation, 84–85
breast, 82–86
cultivation, 85–86
renal, contractile response, activation of cytosolic calcium and, 428–430
Vascular system
parathyroid hormone-related protein in, 144–146
renal microcirculation. *See* Renal microcirculation
Vasoactive factors. *See also specific factors*; Vasoconstrictors; Vasodilators

adenosine interactions, 476–478
differential regulation of renal medullary circulation, 498–502
endothelial-derived, paracrine regulation of renal microcirculation, 433–443
endothelin and renal hemodynamics, 440–443
epithelial-derived, 443–444, 453–456
formation of, 443–444
paracrine regulation of renal microcirculation, 443–444, 453–456
nitric oxide. *See* Nitric oxide
Vasoconstrictors, arachidonic acid metabolite interactions, 493–494
Vasodilators, arachidonic acid metabolite interactions, 494–495
Vasopressin
in blood pressure regulation, 210–211
interactions with peripheral cardiovascular reflexes, 211–212
Vitamin D responsive element, osteocalcin gene, 611–612

W

Water channels
in collecting duct principal cells, 281–283
polarity in epithelial cells, 283
proximal renal tubule, 279–280
Water taste, 749–750
Wilson's disease, 41–42
Wound healing, in *op/op* mouse, role of macrophages, 941

X

***Xenopus* spp.,** swim pattern generators, 695–697

Y

Yeast
ferrireductases in iron uptake, 36
iron transport systems, 40–41
high-affinity transport systems, 40
low-affinity transport systems, 40–41
oxygen effects, 850–858
oxygen adaptation and energy metabolism, 851–852
cytochrome-*c* oxidase as regulator of aerobic energy production, 851
oxygen-regulated cytochrome-*c* isoforms, 852
oxygen-regulated cytochrome-*c* oxidase subunit V isoforms, 851–852
regulation of aerobic genes, 854–856
HAP1 (CYP1)p, 855–856
HAP2/3/4p, 856
regulation of hypoxic genes, 856–857
respiration and oxidative stress, 852–853
transcription and, 853–857
heme as effector molecule, 853
oxygen thresholds for gene expression, 853–854
regulation of aerobic genes, 854–856

Z

Z disks
α-actinin isoforms, 382
CapZ and other Z-disk components, 382